


Adaptation of the British Society of Gastroenterology guidelines on the management of acute severe ulcerative colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

Journal:	Gut
Manuscript ID	gutjnl-2020-321927.R1
Article Type:	Original research
Date Submitted by the Author:	25-May-2020
Complete List of Authors:	Din, Shahida; Western General Hospital, Dept of Gastroenterology ; University of Edinburgh Western General Hospital, Research Scotland Clinician Kent, Alexandra; King's College Hospital NHS Foundation Trust, Dept of Gastroenterology; King's College London Pollok, Richard; St George's Healthcare NHS Trust, Dept of Gastroenterology; St George's University Hospitals NHS Foundation Trust, Institute of Infection and Immunity Meade, Susanna; Guy's and Saint Thomas' Hospitals NHS Trust, Dept of Gastroenterology Kennedy, Nicholas; Royal Devon and Exeter NHS Foundation Trust, Dept of Gastroenterology; University of Exeter, Exeter IBD Research Group Arnott, Ian; Western General Hospital, Dept of Gastroenterology Beattie, R; Southampton Children's Hospital, Dept of Paediatric Gastroenterology Chua, Felix; Royal Brompton Hospital, Interstitial Lung Disease Unit, Department of Respiratory Medicine, Cooney, Rachel; Queen Elizabeth Hospital Birmingham, Dept of Gastroenterology Galloway, James; King's College Hospital, Dept of Rheumatology Galloway, James; King's College Hospital, Dept of Rheumatology Galloway, James; King's College Hospital, Dept of Rheumatology Galloway, James; King's College Hospital, Dept of Gastroenterology Galloway, James; King's College Hospital Birmingham, Dept of Gastroenterology Griffiths, Mark; Barts Health NHS Trust, Peri-operative medicine; National Heart and Lung Institute Hancock, Laura; Manchester University NHS Foundation Trust, Dept of General Surgery Hansen, Richard; Glasgow Royal Infirmary, Paediatric Gastroenterology and Nutrition Hart, Ailsa; St Mark's Hospital, IBD Unit; Imperial College, APRG Lamb, Christopher; Newcastle University, Institute of Cellular Medicine; Newcastle upon Tyne Hospitals NHS Foundation Trust, Gastroenterology; Lees, Charlie; Western General Hospital, Dept of Gastroenterology; University NHS Foundation Trust, Gastroenterology; Lees, Charlie; Western General Hospital, Dept of Gastroenterology; Manchester Academic Health Science Centre

59

60

2		
3		Lindsay, James; Barts Health NHS Trust, Dept of Gastroenterology
4		Patel, Kamal; St George's University Hospitals NHS Foundation Trust,
5		Dept of Gastroenterology
6		Powell, Nick; Imperial College London, Division of Digestive Diseases
7		Murray, Charles; Royal Free Hospital, Dept of Gastroenterology
8		Probert, Chris; University of Liverpool Institute of Translational Medicine,
9		Gastroenterology Research Unit, Department of Cellular and Molecular
10		Physiology,
11		Raine, Tim; Cambridge University Hospitals NHS Foundation Trust, Dept
12		of Gastroenterology
		Selinger, Christian; Leeds Teaching Hospitals NHS Trust
13		Sebastian, Shaji; Hull University Teaching Hospitals NHS Trust, Dept of
14		Gastroenterology; Hull York Medical School
15		Smith, Philip J ; Royal Liverpool University Hospital, Dept of
16		Gastroenterology
17		Tozer, Phil ; St Mark's Hospital and Academic Institute, IBD Unit
18		Ustianowski, Andrew; North Manchester General Hospital Younge, Lisa ; Crohn's and Colitis UK; St Mark's Hospital and Academic
19		
		Institute
20		Samaan, Mark; Guy's and Saint Thomas' Hospitals NHS Trust Irving, Peter; Guy's and Saint Thomas' Hospitals NHS Trust, Dept of
21		
22		Gastroenterology; King's College London, School of Immunology and
23		Microbial Sciences
24	Keywords:	ULCERATIVE COLITIS, CLINICAL DECISION MAKING, IBD CLINICAL
25	Reywords.	DECENTIVE COEFTIS, CENTERE DECISION MARING, IDD CENTERE
26		
27		
28		
29		SCHOLARONE [™]
30		Manuscripts
31		Manuscripts
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
20		
50		



BMJ

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

for Review Only

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe ulcerative colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

Authors

- Shahida Din (Department of Gastroenterology, Western General Hospital, Edinburgh, UK)*
- Alexandra Kent (Department of Gastroenterology, King's College Hospital NHS Foundation Trust, London, UK) *
- 3. Richard C Pollok (Department of Gastroenterology, St Georges University Hospitals NHS Foundation Trust, London, UK) *
- Susanna Meade (Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK) *
- 5. Nicholas A Kennedy (Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK)
- Ian Arnott (Department of Gastroenterology, Western General Hospital, Edinburgh, UK)
- 7. R Mark Beattie (Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK)
- Felix Chua (Interstitial Lung Disease Unit, Department of Respiratory Medicine, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London)
- 9. Rachel Cooney (Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, UK)

10. Robin J. Dart (Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK)

- 11. James Galloway (Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK)
- 12. Daniel R Gaya (Gastroenterology Unit, Glasgow Royal Infirmary, Castle Street, Glasgow, UK)
- 13. Subrata Ghosh (Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, UK)
- 14. Mark Griffiths (Peri-operative medicine, St Bartholomew's Hospital, London, UK)
- 15. Laura Hancock (Manchester University Foundation Trust, Manchester, UK)
- 16. Richard Hansen (Glasgow Royal Infirmary, Glasgow, UK and University of Glasgow, Glasgow, UK)
- 17. Ailsa Hart (IBD Unit, St Mark's Hospital, London, UK)
- Christopher A Lamb (Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK)
- 19. Charlie W Lees (Department of Gastroenterology, Western General Hospital, Edinburgh, UK)
- 20. Jimmy K Limdi (Department of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester, UK)
- 21. James O Lindsay (Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK)
- 22. Charlie D Murray (Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK)
- 23. Kamal Patel (Department of Gastroenterology, St Georges University Hospitals NHS Foundation Trust, London, UK)
- 24. Nick Powell (Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK)
- 25. Chris Probert (Gastroenterology Research Unit, Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK)

Gut

1 2	
3	26. Tim Raine (Department of Gastroenterology, Cambridge University Hospitals
4 5	NHS Foundation Trust, Cambridge, UK)
6 7	
8	27. Christian Selinger (Department of Gastroenterology, Leeds Teaching
9 10	Hospitals, NHS Trust, Leeds, UK)
11	28. Shaji Sebastian (IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull,
12 13	UK)
14	29. Philip J Smith (Department of Gastroenterology, Royal Liverpool Hospital,
15 16	
17	Liverpool, UK)
18 19	30. Phil Tozer (IBD Unit, St Mark's Hospital, London, UK)
20	31. Andrew Ustianowski (Dept of Infectious Disease, North Manchester General
21 22	Hospital, Manchester, UK)
23	32. Lisa Younge (IBD Unit, St Mark's Hospital, London UK)
24 25	
26	33. Mark A Samaan (Department of Gastroenterology, Guy's and St Thomas' NHS
27 28	Foundation Trust, London UK)
29	34. Peter M Irving (School of Immunology and Microbial Sciences, King's College
30 31	London, UK)
32 33	
33 34	* Joint first authors
35 36	
37	
38 39	Corresponding Author:
40	
41 42	Peter M Irving, College House, St Thomas' Hospital, Westminster Bridge Road,
43	London, SE1 7EH, UK.
44 45	
46	E: Peter.irving@gstt.nhs.uk
47 48	
49	
50 51	T: +44 207 188 2491
52	
53 54	F: +44 207 188 2484
55	
56 57	Key words: Ulcerative colitis, clinical decision making, IBD clinical
58	Rey works, orderative contis, clinical accision making, IDD clinical
59 60	

Abbreviations:

Acute severe ulcerative colitis (ASUC)

Novel coronavirus 2019 (COVID-19)

British Society of Gastroenterology (BSG)

RAND/UCLA (Research and Development/University of California, Los Angeles)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Disagreement index (DI)

Inflammatory bowel disease (IBD)

World Health Organisation (WHO)

Physician response to disease flares and patient adaptation in response to events in inflammatory bowel disease during the COVID-19 pandemic (PREPARE IBD)

5-aminosalicylic acid (5-ASA)

Computed tomography (CT)

Anti-tumour necrosis factor (anti-TNF)

International Organisation For the Study of Inflammatory Bowel Disease (IOIBD)

Middle Eastern Respiratory Syndrome (MERS)

Chest x-ray (CXR)

1	
2	
3	Venous thromboembolism (VTE)
4	
5	
6	Clinical Deserve (CDC)
7	Clinical Research Group (CRG)
8	
9	
10	MMX (multi-matrix).
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	Word count: 4408
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	

Abstract

Objective

Management of acute severe ulcerative colitis (ASUC) during the novel coronavirus 2019 (COVID-19) pandemic presents significant dilemmas. We aimed to provide COVID-19-specific guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point.

Design

We convened a RAND appropriateness panel comprising 14 gastroenterologists and an IBD nurse consultant supplemented by surgical and COVID-19 experts. Panellists rated the appropriateness of interventions for ASUC in the context of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Median scores and disagreement index (DI) were calculated. Results were discussed at a moderated meeting prior to a second survey.

Results

Panellists recommended that patients with ASUC should be isolated throughout their hospital stay and should have a SARS-CoV-2 swab performed on admission. Patients with a positive swab should be discussed with COVID-19 specialists.

As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was their use deemed uncertain. In patients requiring rescue therapy, infliximab with continuing steroids was recommended. Delaying colectomy because of COVID-19 was deemed inappropriate.

Steroid tapering as per BSG guidance, was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4-6-week taper was preferred. Post-

ASUC maintenance therapy was dependent on SARS-CoV-2 status but, in general, biologics were more likely to be deemed appropriate than azathioprine or tofacitinib. . tit LOV-2 sw. Panellists deemed prophylactic anticoagulation post-discharge to be appropriate in patients with a positive SARS-CoV-2 swab.

Conclusion

We have suggested COVID-19-specific adaptations to the BSG ASUC guideline using a RAND Panel.

Significance of the Study

What is already known on this subject?

- The BSG has published evidence-based guidelines for management of patients with ASUC, but it is unknown whether these are appropriate in the setting of SARS-CoV-2.
- Currently there are limited data to inform clinicians in this area and there is no published guidance for the management of ASUC in the setting of the COVID-19 pandemic.

What are the new findings?

- The current BSG IBD guidelines provide a management pathway which remains largely appropriate during the COVID-19 pandemic.
- However, some treatment options were deemed uncertain or inappropriate in patients with established COVID-19 pneumonia.
- It is appropriate to involve COVID-19 specialists in decision-making for ASUC patients who are SARS-CoV-2 positive.
- Steroid tapering as per BSG guidance, was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4-6-week taper was preferred.
- Prophylactic anticoagulation post-discharge is appropriate in patients with a positive SARS-CoV-2 swab

How might it impact on clinical practice in the foreseeable future?

This paper summarises available evidence and provides expert opinion for the appropriate management of patients with ASUC during the COVID-19 pandemic.

It also highlights areas of uncertainty which may help direct areas of future research.

Contributors

All authors approved the final version. Study concept and design: SD, RP, AK, MS, PI. Development of questionnaire: SD, RP, AK, SM, PI, MS, NK. Data Analysis: PI, MS, SM. Interpretation of data and drafting of manuscript: SD, RP, AK, SM, MS, NK, PI. Panellists, experts and moderators: SD, AK, RP, SM, NK, JOL, CAL, JKL, CP, CS, SS, DRG, TR, RD, AH, LY, CWL, IA, FC, JG, AU, MG, PT, LH, MS, SM, PI Contributions to literature ι t review and critical revision of the manuscript for important intellectual content: All authors

ORCID iDs

SD 0000-0003-2855-3400

AK 0000-0003-0577-6177

RP 0000-0001-6452-6763

SM 0000-0002-8283-6148

NK 0000-0003-4368-1961

IA 0000-0003-3352-925

MB 0000-0003-4721-0577

FC 0000-0001-7845-0173

RC 0000-0003-3710-157X

RD 0000-0003-3470-8210

JG 0000-0002-1230-2781

DRG 0000-0003-1942-7568

SG 0000-0002-1713-7797

MG 0000-0002-1615-1896

LH 0000-0002-8399-6646

RH 0000-0002-3944-6646

AH 0000-0002-7141-6076

CAL 0000-0002-7271-4956

CWL 0000-0002-0732-8215

JKL 0000-0002-1039-6251

JOL 0000-0003-3353-9590

KP 0000-0003-2611-4260

NP 0000-0003-3231-6950

CM 0000-0001-6736-1546

CP 0000-0003-0477-6714

al. to Review Only

Gut

TR 0000-0002-5855-9873

CS 0000-0003-2022-5859

SS 0000-0002-3670-6545

PJS 0000-0003-1568-3978

PT 0000-0002-2532-7267

LY 0000-0002-3436-9696

r. to peries only MAS 0000-0002-4057-9200

PMI 0000-0003-0972-8148

Introduction

The novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was first reported in December 2019 and its spread led to the declaration of a pandemic by the World Health Organisation (WHO) on 11th March 2020. Infection varies in severity from asymptomatic carriage to an acute respiratory illness which, at its most severe, results in acute respiratory distress syndrome with hyperinflammation and cytokine storm syndrome.[1] By mid-May 2020, there have been nearly 5 million cases reported worldwide with over 300,000 deaths.[2] Risk factors associated with more severe coronavirus disease 2019 (COVID-19) include older age, male sex, hypertension, cardiovascular disease, respiratory disease, diabetes, renal failure, and ethnicity.[3] Neither an effective medical therapy nor a vaccine has yet been described, although numerous candidates are under evaluation.

Acute severe ulcerative colitis (ASUC) occurs in up to 25% of patients with UC and is associated with a mortality of approximately 1%.[4,5] The management of ASUC is particularly challenging in the context of SARS-CoV-2 as the typical presenting features of ASUC, namely diarrhoea with raised inflammatory markers, often in association with a fever, may mimic those of COVID-19. ASUC is managed with high dose parenteral corticosteroids, progressing to rescue therapy and/or surgery in those who fail to respond adequately.[6] The safety of all of these interventions in the context of COVID-19 infection is unclear. For example, there are concerns that corticosteroids may increase the risk of acquiring SARS-CoV-2 infection and/or worsen the severity of COVID-19 disease.[7] In addition, the commonly used rescue therapies, infliximab and ciclosporin are associated with an increased risk of infection, particularly if used in combination with immunomodulators such as thiopurines, or steroids.[8] Finally, individuals in whom corticosteroids and rescue therapy fail require urgent colectomy which is associated with high morbidity and mortality in patients infected with SARS-CoV-2.[9] However, withholding treatment in ASUC is clearly not an option in view of the high mortality (in excess of 20%) associated with such an approach.[10]

Page 15 of 92

Gut

Whilst national and international registries continue to collate data regarding IBD patients with COVID-19, very few cases relate to the management of ASUC. The PREPARE IBD study (www.prepareibd.org) is collecting data from patients with inflammatory bowel disease (IBD) who are admitted to hospital during the pandemic, as well as from those who develop confirmed or suspected SARS-CoV-2 infection. As of 8th May 2020, 19 patients with severe active UC including four with suspected or confirmed COVID-19 had been identified (personal communication, manuscript submitted). The Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-IBD registry (https://covidibd.org/) is collating data on IBD patients with confirmed coronavirus, with 1074 patients included to date, the majority of whom have Crohn's disease; details of how many in the cohort have ASUC are not yet available.[11] Finally, in case series from Italy and Spain, 4 of 79 and 1 of 40 patients respectively had COVID-19 in conjunction with ASUC [12,13] (the number of ASUC patients in the Italian case series was provided on request from authors).

Treatment of ASUC during the COVID-19 pandemic presents substantial management dilemmas in the absence of a high-quality evidence base to guide clinicians. We therefore aimed to address this deficit of informed guidance by convening a RAND appropriateness panel. Current BSG guidelines were used as a reference point to highlight differences to current management.[6]

Methods

Study Overview

The RAND/UCLA (University of California, Los Angeles) appropriateness method uses a modified Delphi panel approach and combines expert opinion with the best available evidence to determine the appropriateness of specific practices in certain clinical situations.[14] It is particularly useful in areas of uncertainty in which evidence is insufficient to guide day-to-day clinical practice, such as in the COVID-19 pandemic.[15] The aim of this RAND panel was to provide clarity on the management of ASUC, as defined by Truelove and Witts criteria, in the context of the COVID-19 pandemic.[10] The panel sought to identify areas where it was appropriate to deviate from current BSG ASUC guidance and consider alternative strategies.

Gut

We assembled a 15-person panel comprising representatives from the BSG IBD Section Committee, the BSG IBD Clinical Research Group (CRG) and other gastroenterologists, each from different IBD centres across the UK, as well as an IBD nurse consultant (supplementary Table 1). A web-based questionnaire was created and iteratively improved before being completed by all panellists prior to a moderated online meeting. We circulated a list of relevant publications with the questionnaire, comprising the current BSG guidelines on the management of ASUC[6] along with up to date publications about COVID-19 in general and specifically in relation to IBD. Due to the rapid growth of available data, the panel used a range of instant messaging services to disseminate publications that were not available at the time of the initial literature review.

Panellists rated the appropriateness of management options at five different time points during the course of admission for ASUC (admission, first line therapy, rescue therapy, continued medical therapy and surgery) in the context of absence of, or varying severity of SARS-CoV-2 infection. They were asked to grade the appropriateness of specific interventions on a scale of 1-9 (where 1-3 is inappropriate, 4-6 is uncertain and 7-9 is appropriate). The responses were summarised and anonymised before being presented at a virtual meeting in May 2020 with the aim of allowing discussion which ensured a common understanding of the questions and which focussed on areas of disagreement, without trying to force consensus. Also present at the meeting were non-voting specialists who provided expert opinion with regards to IBD surgery (PT, LH), rheumatology (JG), intensive care (MG), respiratory medicine (FC) and infectious diseases (AU). In practice, several specialities may provide expert opinion in COVID-19 management, including intensivists, respiratory physicians and infectious disease physicians. We, therefore, used the encompassing term "COVID-19 specialist" to represent this group. Finally, the Chairs of the BSG IBD

Page 17 of 92

 Section Committee (IA) and the BSG IBD Clinical Research Group (CL) were also present. The moderators (PI, MS) neither expressed opinions on management nor voted, but were experts both in RAND panels and in the management of IBD. After the meeting, a second online survey comprising 91 questions, which had been slightly modified from the initial questionnaire following discussion at the meeting, was

Several assumptions were made for clarity. First, patients were assumed to have a confirmed diagnosis of UC with intercurrent gastrointestinal infection having been excluded. Second, if this was not an index presentation, patients were assumed to have received optimised 5-aminosalicylic acid (5-ASA) therapy prior to admission and were also presumed to be biologic-naïve. In addition, where ciclosporin was suggested as an option, it was assumed that the patient was thiopurine-naïve. Third, other than those areas addressed in the survey, the management of ASUC was assumed to be in line with BSG guidance.[6] Finally, where steroid weaning or discontinuation was considered, it was assumed that patients could safely stop steroids without the risk of Addisonian crisis.

In addition, in the section about first line medical therapy, panellists assumed patients were not steroid refractory. For the rescue therapy section, patients were assumed to have ongoing acute severe colitis despite 3 days of intravenous corticosteroid therapy and had reached standard criteria for rescue therapy.[16] For the continuing medical therapy section, patients were assumed to have responded to intravenous corticosteroids sufficiently to switch to oral prednisolone and were ready to be discharged from hospital. Lastly, as per RAND methodology, respondents were advised to make decisions without considering local availability of treatments or cost.

Analysis

circulated for completion.

For each scenario, median scores were calculated with a score of <3.5 being considered inappropriate, \geq 3.5 but <6.5 uncertain, and \geq 6.5 appropriate. We used the validated RAND disagreement index (DI) to define disagreement amongst panellists

using the equation outlined below.[14] A $DI \ge 1$ denotes disagreement. Any scenario in which disagreement was found was scored as uncertain, regardless of the median score.

$$DI = \frac{70\% ile - 30\% ile}{2.35 + \left(1.5 \times abs\left(5 - \frac{70\% ile + 30\% ile}{2}\right)\right)}$$

Results

Overall Results

Of the 91 clinical scenarios, panellists rated 28 as appropriate, 19 as uncertain and 44 as inappropriate. After the second round of voting, agreement was present for all scenarios (DI<1). The key findings are summarised below and their relationship to current BSG guidance is highlighted in figure 1. A detailed list of all scenarios, complete with median score, appropriateness rating and DI can be found in supplementary Table 2.

Indications for investigations, inpatient isolation and specialist referral (Table 1)

The panellists agreed that all patients admitted to hospital with ASUC should have a SARS-CoV-2 swab performed on admission. If the result was negative it was deemed appropriate to repeat the swab at the point of requiring rescue therapy and/or surgery to exclude subclinical infection. It was also considered appropriate to isolate all patients throughout their hospital stay, irrespective of their COVID-19 status.

It was rated appropriate to perform a flexible sigmoidoscopy within 24 hours of admission. If a patient had not had a flexible sigmoidoscopy on admission, it was considered appropriate that one should be performed prior to rescue therapy or colectomy. Repeating this test at these timepoints was deemed unnecessary in patients who had already had a flexible sigmoidoscopy performed.

Routine computed tomography (CT) scanning of the abdomen/pelvis on admission (in addition to abdominal X-ray) was deemed inappropriate. However, the

appropriateness of routine chest CT on admission was rated as uncertain. The one scenario in which a CT scan of the chest was felt to be appropriate for all patients irrespective of COVID-19 status was in the context of patients requiring colectomy.

Throughout the scenarios, the panellists considered the appropriateness of discussion with COVID-19 specialists. In patients without symptoms or signs of COVID-19 and una, rescue th a positive swa. with a negative swab this was deemed inappropriate if receiving first line therapy but uncertain in patients requiring rescue therapy. However, it was considered appropriate in all patients with a positive swab, irrespective of the presence of symptoms or signs of COVID-19.

	On admission	Prior to Rescue therapy	Prior to colectomy
Inpatient Isolation		All patients	
SARS-CoV-2 swab	Perform in all patients	Repeat swab if initial swab negative	Repeat swab if initial swab negative
Flexible sigmoidoscopy	≤24h admission	If not performed	If not performed
		If already performed	If already performed
CT chest	Perform in all patients		Perform in all patients
CT abdomen & pelvis	Perform in all patients		

Table 1. Appropriateness of patient isolation and investigation in patients admitted with acute severe ulcerative colitis in the context of the COVID-19 pandemic. (Green is considered appropriate, yellow uncertain and red inappropriate).

Initial Treatment of ASUC (Table 2)

As per BSG guidance, intravenous hydrocortisone, 100mg, four times per day (or equivalent) was rated appropriate as the initial management of patients presenting with ASUC in the absence of symptoms and signs of COVID-19 pneumonia. In patients with COVID-19 pneumonia, use of hydrocortisone was deemed uncertain. Other possible treatments (poorly bioavailable oral steroids e.g. budesonide multi-matrix (MMX) and beclometasone modified release, infliximab either with or without steroids, ciclosporin or tofacitinib) were considered inappropriate. The exception was infliximab (without steroids) which was considered uncertain in patients with a positive swab for SARS-CoV-2, either with or without signs of COVID-pneumonia. Ambulatory outpatient management with daily intravenous methylprednisolone was rated as inappropriate in all patients with ASUC regardless of SARS-CoV-2 status, as .ton. .s toxic m. was management by immediate colectomy unless complications mandating emergency surgery were present such as toxic megacolon, perforation or severe haemorrhage.

	First line medical therapy				
Negative COVID swab WITHOUT	*Inpatient IV steroids	Poorly bioavailable steroids	IFX alone	Tofacitinib	^Discussion with COVID-19 specialist
respiratory symptoms	**Ambulatory IV steroids	IV steroids* + IFX	Ciclosporin	Colectomy	
Positive COVID swab WITHOUT respiratory	*Inpatient IV steroids	Poorly bioavailable steroids	IFX alone	Tofacitinib	^Discussion with COVID-19 specialist
symptoms or signs of COVID pneumonia	**Ambulatory IV steroids	IV steroids* + IFX	Ciclosporin	Colectomy	
Positive COVID swab WITH symptoms or signs of COVID pneumonia	*Inpatient IV steroids	Poorly bioavailable steroids	IFX alone	Tofacitinib	^Discussion with COVID-19 specialist
	**Ambulatory IV steroids	IV steroids* + IFX	Ciclosporin	Colectomy	

Table 2. Appropriateness of treatment options in acute severe ulcerative colitis in the context of the COVID-19 pandemic: First line medical therapy. (Green is considered appropriate, yellow uncertain and red inappropriate). *Steroids, intravenous (IV) hydrocortisone 100mg QDS or IV methylprednisolone 60mg daily as an inpatient; **IV Methylprednisolone 60mg daily as an outpatient; *****Budesonide MMX 9 mg/beclometasone 5 mg OD PO as an inpatient; IFX, Infliximab (either 5mg/kg or 10mg/kg); ^Discussion with appropriate COVID-19 specialist as per local availability.

Page 23 of 92

In patients meeting criteria for escalation of management at day 3, it was considered inappropriate to avoid rescue therapy by continuing monotherapy with intravenous corticosteroids, irrespective of COVID status. Instead, the panellists deemed that following standard BSG guidance by initiating infliximab and continuing steroids was appropriate, whereas treatment with infliximab in conjunction with immediate steroid withdrawal was deemed uncertain. The BSG guidelines also recommend ciclosporin as an alternative rescue therapy. However, the RAND panel voted that ciclosporin, either with or without ongoing steroids, was inappropriate in all scenarios other than in patients with a negative SARS-CoV-2 swab in whom it was rated uncertain. Finally, colectomy without rescue therapy was deemed inappropriate in all of the scenarios considered by the panel. However, once colectomy became necessary, for example where rescue therapy had failed or when complications had occurred, it was deemed inappropriate to delay surgery, even in patients with COVID-19 pneumonia.

	Rescue therapy			Failure of Rescue Therapy	
Negative COVID swab WITHOUT respiratory symptoms	Continue IV steroids alone	IFX + steroids	IV ciclosporin + steroids	Colectomy	Delay surgery
		IFX, stop steroids	IV ciclosporin, stop steroids	^Discussion with COVID-19 specialist	
Positive COVID swab WITHOUT respiratory symptoms or signs of COVID pneumonia	Continue IV steroids alone	IFX + steroids	IV ciclosporin + steroids	Colectomy	Delay surgery
		IFX, stop steroids	IV ciclosporin, stop steroids	^Discussion with COVID-19 specialist	
Positive COVID swab WITH symptoms or signs of COVID pneumonia	Continue IV steroids alone	IFX + steroids	IV ciclosporin + steroids	Colectomy	Dolou surgery
		IFX, stop steroids	IV ciclosporin, stop steroids	^Discussion with COVID-19 specialist	Delay surgery

Table 3. Appropriateness of treatment options in acute severe ulcerative colitis in the context of the COVID-19 pandemic: Rescue therapy. (Green is considered appropriate, yellow uncertain and red inappropriate). Steroids, Intravenous (IV) hydrocortisone 100mg QDS or IV methylprednisolone 60mg daily as an inpatient; IFX: Infliximab (either 5mg/kg or 10mg/kg); ^Discussion with appropriate COVID-19 specialist as per local availability.

Continuing medical therapy (Table 4)

The ongoing management of patients who had responded to intravenous corticosteroids and were ready for discharge on oral steroids was also considered. In patients with a negative SARS-CoV-2 swab, or with a positive swab but without signs or symptoms of pneumonia, steroid tapering over 6-8 weeks as per BSG guidance was deemed appropriate. However, in patients with COVID-19 pneumonia it was rated uncertain. Accelerated steroid withdrawal over 4-6 weeks was rated appropriate regardless of COVID-19 status. More rapid withdrawal over 4 weeks was deemed inappropriate except in patients with COVID-19 pneumonia, in whom it was rated uncertain. The use of poorly bioavailable oral steroids as an alternative to a standard steroid taper was rated as inappropriate in all scenarios

Initiation of additional therapy prior to, or soon after discharge to prevent relapse was also considered. Following BSG guidance by initiating a thiopurine was rated uncertain in SARS-CoV-2 swab-negative patients, and inappropriate in swab-positive patients. Use of biological therapy (anti-tumour necrosis factor (TNF), ustekinumab or vedolizumab) was deemed appropriate in swab-negative patients. In all other patients, the appropriateness of biological therapy was uncertain, except for anti-TNF therapy in patients with a positive swab but without pneumonia in whom treatment was rated as appropriate. Tofacitinib was generally rated as inappropriate except in swab-negative patients in whom it was rated uncertain.

Finally, panellists were asked whether patients should be discharged with a period of ongoing prophylactic anticoagulation. This was deemed appropriate in patients who had a positive SARS-CoV-2 swab regardless of whether they had pneumonia but was rated uncertain in those who had negative swabs.

	Continuing medical therapy∞				
Negative COVID swab WITHOUT respiratory symptoms	Standard steroid taper	Accelerated steroid taper <4 weeks	°Thiopurine	°Ustekinumab	°Tofacitinib
	Accelerated steroid taper 4-6 weeks	◆Poorly bioavailable steroids	°Anti-TNF	°Vedolizumab	⊙Thromboprophylaxis
Positive COVID swab WITHOUT respiratory symptoms or signs of COVID pneumonia	Standard steroid taper	Accelerated steroid taper <4 weeks	°Thiopurine	°Ustekinumab	°Tofacitinib
	Accelerated steroid taper 4-6 weeks	◆Poorly bioavailable steroids	°Anti-TNF	°Vedolizumab	⊙Thromboprophylaxis
Positive COVID swab WITH symptoms or signs of COVID pneumonia	Standard steroid taper	Accelerated steroid taper <4 weeks	°Thiopurine	°Ustekinumab	°Tofacitinib
	Accelerated steroid taper 4-6 weeks	◆Poorly bioavailable steroids	°Anti-TNF	°Vedolizumab	 Thromboprophylaxis

Table 4. Appropriateness of treatment options in acute severe ulcerative colitis in the context of the COVID-19 pandemic: Continuing medical therapy. (Green is considered appropriate, yellow uncertain and red inappropriate). ∞Patient has responded to intravenous steroid therapy;
Switch from corticosteroids to budesonide MMX 9 mg daily/beclometasone 5 mg daily; °Steroid taper and start additional therapy at or soon after discharge; ⊙Continue for a period after discharge.

Discussion

General Considerations

The recent International Organisation For the Study of Inflammatory Bowel Disease (IOIBD) RAND appropriateness panel addressing the use of medications to treat IBD in the COVID-19 era did not specifically address the management of patients with ASUC.[17] To date, there has been no consensus on how to manage this condition during the COVID-19 pandemic; in the context of a limited, although rapidly evolving evidence base, this is perhaps unsurprising.[18] Thus, there is an urgent need for guidance on how best to manage ASUC in the current setting. Several areas need consideration in this regard including: the effect of SARS-CoV-2 on the activity and course of IBD; the effect of IBD and its activity on the risk of being infected with SARS-CoV-2 and the progression to COVID-19; the interaction of SARS-CoV-2/COVID-19 with the drugs used to treat IBD; and the possible effects of treatments for COVID-19 on IBD.

SARS-CoV-2 is found in the gut and RNA is measurable in the stool significantly longer than in serum or respiratory samples [19] although the significance of this is unclear. The effects of the virus on the intestinal mucosa remain undefined, as does its interaction with inflamed tissue.[20] Gastrointestinal symptoms including diarrhoea occur in around 30% of patients and have been associated with worse outcome [21,22] and a single report describes a possible case of COVID-19 colitis.[23]

Currently, it is not clear whether IBD-specific factors lead to worse outcomes in patients who develop COVID-19. In the Italian series of 79 patients with IBD and COVID-19, active disease was associated with the risk of COVID-19 pneumonia even after controlling for other risk factors.[12] Furthermore, active IBD was also significantly associated with increased hospitalisation, the need for respiratory support and death. In contrast, in Bergamo, Northern Italy, an observational study reported no cases of COVID-19 in 522 patients with IBD.[24] Whilst there are data that

suggest that active IBD increases the risk of some viral infections,[25] it is difficult to draw firm conclusions with regard to SARS-CoV-2 infection given the limited data available.

Of concern to most clinicians caring for patients with IBD is the possible risk of the drugs used to manage ASUC in the context of the COVID-19 pandemic. Intravenous corticosteroids remain the most widely used induction therapy in ASUC [26], but it is uncertain how they may influence outcome in patients with SARS-CoV-2 infection and COVID-19. Corticosteroids are known to increase the risk of sepsis and respiratory tract infections and may also increase viral replication and susceptibility to SARS-CoV-2.[27,28] There is also evidence that steroids may increase morbidity and/or mortality from some respiratory viruses such as influenza, Middle Eastern Respiratory Syndrome (MERS) and SARS-CoV, [27, 29–31] although steroids have an established role in the management of ARDS.[32] Beyond corticosteroids, immunomodulators such as thiopurines, biologics and tofacitinib are frequently used at various stages of the management of ASUC and there is also a lack of data regarding their safety in the context of the SARS-CoV-2 pandemic. Finally, it is important to consider the possible effects of drugs used to manage COVID-19 on IBD. For example, interleukin-6 inhibitors are being tested in patients with COVID-19 (ClinicalTrials.gov Identifier: NCT04315298) but have been associated with intestinal perforation in IBD.

We used an established methodology, a RAND appropriateness panel, to produce guidance in this challenging clinical area. Regarding initial management, there was agreement that all patients with ASUC should be managed as inpatients. Ambulatory care was considered inappropriate, since patients with ASUC need regular monitoring and involvement of a multi-disciplinary team, this type of complex care being difficult to deliver in the out-patient setting. Whilst there was some support for ambulatory management to avoid patients being admitted, thereby decreasing the risk of nosocomial acquisition of SARS-CoV-2, the risks of managing ASUC as an outpatient were considered to outweigh this possible benefit. Furthermore, in scenarios in which patients had confirmed SARS-CoV-2 infection, no such benefit existed. Nevertheless, in view of the acknowledged risk of contracting SARS-CoV-2 infection in hospital, it is

 perhaps unsurprising that the panel considered it appropriate to isolate patients with ASUC in a side room wherever possible.

The panel deemed it uncertain whether a CT chest should be performed in all patients on admission. While a CT chest is more sensitive than a chest x-ray (CXR) in detecting signs of early or limited infection, the COVID-19 specialists advised that a CXR would suffice in asymptomatic patients on admission. However, The Royal College of Radiologists has advised a low dose CT chest should be performed in patients who are having a CT abdomen as part of the investigation of an abdominal emergency.[33–35]

It was considered appropriate to involve a COVID-19 specialist in all scenarios in the presence of a positive SARS-CoV-2 swab, regardless of signs or symptoms of COVID-19 pneumonia. The panel was uncertain whether this was required in patients with a negative SARS-CoV-2 swab who required rescue therapy. During the meeting, concern was expressed by some panellists about the possible effects of corticosteroids and rescue therapies on SARS-CoV-2 infection and COVID-19 pneumonia driving the need to seek clarification from COVID experts and highlighting the need for further research.

First Line Therapy

It was considered appropriate to follow the BSG guidelines on the initial management of ASUC in patients without signs or symptoms of COVID-19, regardless of SARS-CoV-2 swab results. Only in patients with COVID-19 pneumonia was there uncertainty amongst the panel regarding the appropriateness of conventional therapy with intravenous corticosteroids, largely driven by concerns of possible harm. However, it should be noted that in this challenging condition in which there is scant experience and almost no published data in relation to COVID-19, of all suggested treatments, intravenous corticosteroids were given the highest median score by the panel. Regarding the ongoing uncertainty about the benefits or harms of corticosteroids in patients with COVID-19 pneumonia and the inconclusive data emerging from the current coronavirus pandemic, the results of the adaptive trial, RECOVERY, which includes a dexamethasone arm, are eagerly awaited.[1] Nevertheless, leaving ASUC untreated is associated with a high risk of death, mortality being at least 24% in the days before the use of corticosteroids.[26] The expert advisers supported the WHO position that steroid use should not be avoided because of theoretical risks in patients with COVID-19.[36]

The panel was uncertain whether infliximab, without concurrent corticosteroids, should be used as a first line therapy in patients who are SARS-CoV-2 positive, regardless of whether they had COVID-19. As with corticosteroids, the risk of anti-TNF in the context of the pandemic is unknown. In addition, there is no high-quality evidence for infliximab in ASUC other than as a rescue therapy following corticosteroid failure. Anti-TNF agents are known to increase the risk of respiratory tract and other opportunistic infections,[37] particularly when used in association with thiopurines and corticosteroids.[38] However, anti-TNF therapies are currently being evaluated in clinical trials [39] as a potential treatment for COVID-19-induced cytokine 'storm' [40,41]. In view of the uncertainty of the effects of corticosteroids and infliximab on SARS-CoV-2 infection, it was considered appropriate that all patients with a positive swab should be discussed with a COVID-19 specialist to guide decision making.

Rescue Therapy

Up to half of patients with ASUC fail first line medical therapy with corticosteroids.[6] In all scenarios, it was considered inappropriate to continue this treatment alone in the face of non-response at day 3, consistent with current BSG guidelines.[6] Similarly, in line with BSG guidance, it was considered appropriate to commence infliximab whilst continuing corticosteroids regardless of SARS-CoV-2 status. Discontinuation of corticosteroids at the point of commencing infliximab rescue therapy was considered of uncertain appropriateness across all scenarios, as it may result in worsening colitis, whilst acknowledging the potential risks of combining the two drugs. Ciclosporin rescue therapy was generally considered inappropriate, due in part to concerns about the risks of drug-induced nephrotoxicity given the frequency of acute kidney injury in SARS-CoV-2 infection.[42] In addition, the infusion regimen requires frequent

Page 31 of 92

 Gut

healthcare worker-patient contact which could, in theory, increase the risk of transmission. The panel did not explore its use in settings in which infliximab may be relatively contraindicated, such as previous loss of response to infliximab, drug immunogenicity or when relevant co-morbidities exist, such as multiple sclerosis. Similarly, the panel did not specifically address the question of whether infliximab was used as a monotherapy or in combination with an immunomodulator.

There is little evidence regarding the risks of surgical management in patients with COVID-19. Preliminary data demonstrate a substantial increase in morbidity and mortality amongst SARS-CoV-2-infected patients undergoing surgery (*personal communication, submitted for publication*). In one report, 34 patients underwent elective surgery in Wuhan, China with all developing COVID-pneumonia, 7 of whom (20%) died.[9] Accordingly, the risks of surgery drove the rating of colectomy as first line therapy, or as an alternative to rescue therapy, as being inappropriate. However, in patients failing medical therapy, there was consensus that delaying surgery would be inappropriate.

Continuing Medical Therapy

The BSG IBD guidelines recommend corticosteroid tapering over 6-8 weeks which was considered appropriate by the panel, except in the context of COVID-19 pneumonia where an accelerated taper over 4-6 weeks was considered appropriate instead. A more accelerated taper, over fewer than 4 weeks, was generally deemed inappropriate due to the high risk of relapse in this cohort.[6] Regarding initiation of maintenance therapy either before or shortly after discharge from hospital, it was considered appropriate to start anti-TNF, vedolizumab or ustekinumab in patients with negative swabs. However, in scenarios in which patients had positive swabs, with or without evidence of COVID-19 pneumonia, there was uncertainty about the risk: benefit ratio of biologic therapy, driven by the lack of evidence. Thus, biologic use in this situation was deemed uncertain in nearly all scenarios.

Thiopurines and tofacitinib were not considered appropriate at any stage during the scenarios. This is despite the BSG recommendation that thiopurines should be initiated at or soon after discharge following successful treatment of ASUC.[6] Azathioprine therapy was in part considered inappropriate due to possible side effects such as pancreatitis, which could result in readmission to hospital, and drug hypersensitivity, which can manifest as a flu-like syndrome which may potentially be confused with COVID-19.[43] Azathioprine can also induce significant lymphopaenia [43] which may mimic the lymphopaenia seen in SARS-CoV-2 infection. How this affects outcome of COVID-19 is unclear; some reports even suggest a theoretical benefit of thiopurines.[44,45] The additional monitoring required when azathioprine is initiated may also be a challenge with COVID-19-related service reconfiguration and antecedent risks of SARS-CoV-2 acquisition posed by the requirement for face-to-face contact from laboratory monitoring.

Tofacitinib is a non-selective Janus kinase (JAK) inhibitor which is associated with herpes zoster viral reactivation and, like COVID-19, is also associated with an increased risk of deep vein thrombosis.[46] There is also very limited evidence for its use in the setting of ASUC.[47] For these reasons, the panel considered its use inappropriate in nearly all settings although it was noted that its rapid offset of action could be of theoretical benefit.

Anticoagulation

Prophylactic anticoagulation was considered appropriate beyond discharge amongst patients with a positive SARS-CoV-2 swab, although this strategy was deemed uncertain in people with negative swabs. Like ASUC, COVID-19 is strongly linked to a hypercoagulable state with substantially increased risk of microthrombi and venous thromboembolism (VTE).[48] It is notable that the British Thoracic Society recommends doubling the dose of anticoagulation and/or prescribing VTE prophylaxis (low molecular weight heparin or direct oral anticoagulant) for up to 4 weeks following discharge in high risk patients with COVID-19.[49]

Page 33 of 92

Gut

Strengths & Limitations

The strengths of our study include the inclusion of a diverse group of IBD experts drawn from a wide range of UK centres as well as non-gastroenterology specialists with experience in managing patients with COVID-19. In addition, we used the RAND methodology which is a validated technique to guide decision making in the absence of a robust evidence base. It is not necessarily an attempt to reach consensus but rather to guide clinicians as to the appropriateness or inappropriateness of interventions, whilst accepting that uncertainty is also a valid outcome, which was highly appropriate in this setting. It was impossible for our scenarios to encompass fully all cases encountered in clinical practice. We, therefore, focussed on principles that may help to guide decision making in most cases of ASUC in the context of COVID-19. We appreciate that by doing so, this guidance may not be directly applicable to more nuanced cases where decision making may be influenced by a myriad of factors. Nor was every aspect of care considered; for example, the question of repeating testing for Clostridium difficile prior to colectomy in view of higher exposure to antibiotics in the COVID-19 era, was not addressed. The outcomes should, therefore, be considered an adjunct to multidisciplinary decision-making rather than a replacement. Finally, knowledge within the field remains fast moving such that it will be important to stay abreast of new developments as they arise.

Implications and concluding remarks

By combining clinical expertise from the BSG CRG and IBD Section Committee in conjunction with other medical and surgical IBD and COVID-19 experts, we have provided guidance to clinicians regarding the appropriate management of ASUC during the COVID-19 pandemic, highlighting where current BSG guidance may need adaptation. Population-based studies are needed to clarify the risks and benefits of interventions used in the management of ASUC during the pandemic. Until then, we consider the results of the panel, which largely support following the well-established and evidence-based BSG guideline, will help guide clinicians in this challenging and evolving area.

Acknowledgments

The authors would like to acknowledge the input of Professor Jon Rhodes for his helpful comments and suggestions.

Funding The authors have declared no funding for this research

Competing interests Please see supplementary table 3

References

- Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;**395**:497–506. doi:10.1016/S0140-6736(20)30183-5
- Johns Hopkins University. Johns Hopkins Coronavirus Resource Center.
 2020.https://coronavirus.jhu.edu/ (accessed 8 May 2020).
- 3 The OpenSAFELY Collaborative, Williamson E, Walker AJ, *et al.* OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv* Published Online First: 7 May 2020. doi:10.1101/2020.05.06.20092999
- Turner D, Walsh CM, Steinhart AH, et al. Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression. *Clin Gastroenterol Hepatol* 2007;5:103–10.
 doi:10.1016/j.cgh.2006.09.033
- 5 Seah D, De Cruz P. Review article: the practical management of acute severe

Gut

	ulcerative colitis. Aliment Pharmacol Ther 2016; 43 :482–513.
	doi:10.1111/apt.13491
6	Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology
	consensus guidelines on the management of inflammatory bowel disease in
	adults. <i>Gut</i> 2019; 68 :s1–106. doi:10.1136/gutjnl-2019-318484
7	Rubin DT, Abreu MT, Rai V, et al. Management of Patients with Crohn's
	Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an
	International Meeting. Gastroenterology Published Online First: April 2020.
	doi:10.1053/j.gastro.2020.04.002
8	Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic
	Infections Associated With Treatment of Inflammatory Bowel Diseases.
	Gastroenterology 2018; 155 :337-346.e10. doi:10.1053/j.gastro.2018.04.012
9	Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients
	undergoing surgeries during the incubation period of COVID-19 infection.
	Published Online First: 2020. doi:10.1016/j.eclinm.2020.100331
10	Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a
	therapeutic trial. <i>Br Med J</i> 1955; 2 :1041–8.
11	SECURE-IBD. SECURE-IBD Registry: Surveillance Epidemiology of Coronavirus
) ,	(COVID-19) Under Research Exclusion. 2020.https://covidibd.org/updates-
	and-data/
12	Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with
	IBD in Italy: an IG-IBD study. Gut Published Online First: 30 April 2020.
	doi:10.1136/gutjnl-2020-321411
13	Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, et al. Characteristics and

prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). *Gastroenterology* 2020;**0**. doi:10.1053/j.gastro.2020.04.043

- 14 Fitch K, Bernstein María SJ, Aguilar D, *et al.* The RAND/UCLA Appropriateness Method User's Manual. 2001.
- 15 Coulter I, Elfenbaum P, Jain S, et al. SEaRCH[™] expert panel process: streamlining the link between evidence and practice. BMC Res Notes 2016;9:16. doi:10.1186/s13104-015-1802-8
- 16 Travis SP, Farrant JM, Ricketts C, *et al.* Predicting outcome in severe ulcerative colitis. *Gut* 1996;**38**:905–10. doi:10.1016/j.dld.2004.03.002
- Rubin DT, Abreu MT, Rai V, *et al.* Management of Patients with Crohn's
 Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an
 International Meeting. *Gastroenterology* Published Online First: April 2020.
 doi:10.1053/j.gastro.2020.04.002
- Al-Ani A, Prentice R, Rentsch C, *et al.* Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.
 Aliment Pharmacol Ther Published Online First: 29 April 2020.
 doi:10.1111/apt.15779
- 19 Zheng S, Fan J, Yu F, *et al.* Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* 2020;:m1443. doi:10.1136/bmj.m1443
- Ding S, Liang TJ. Journal Pre-proof Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission: A COVID-19 Virological and Clinical Review. *Gastroenterology* Published Online First: 2020. doi:10.1053/j.gastro.2020.04.052

1		
2 3	21	Dan L. Mu M. Vang D. at al. Clinical Characteristics of COVID 10 Dationts With
4	21	Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With
5 6		Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional,
7		Multicenter Study. Am J Gastroenterol 2020;115:766–73.
8 9		doi:10.14309/ajg.000000000000620
10		
11 12		
13	22	Mao R, Qiu Y, He J-S, et al. Manifestations and prognosis of gastrointestinal
14 15		and liver involvement in patients with COVID-19: a systematic review and
16		meta-analysis. Lancet Gastroenterol Hepatol Published Online First: May 2020.
17 18		doi:10.1016/S2468-1253(20)30126-6
19		
20		
21 22	23	Carvalho A, Alqusairi R, Adams A, et al. SARS-CoV-2 Gastrointestinal Infection
23		Causing Hemorrhagic Colitis. Am J Gastroenterol 2020;:1.
24 25		doi:10.14309/ajg.00000000000667
26		
27 28	~ ^	
29	24	Norsa L, Indriolo A, Sansotta N, et al. Uneventful course in IBD patients during
30 31		SARS-CoV-2 outbreak in northern Italy. <i>Gastroenterology</i> Published Online
32		First: April 2020. doi:10.1053/j.gastro.2020.03.062
33 34		
35	25	Wisniewski A, Kirchgesner J, Seksik P, <i>et al.</i> Increased incidence of systemic
36 37	25	
38		serious viral infections in patients with inflammatory bowel disease associates
39 40		with active disease and use of thiopurines. United Eur Gastroenterol J
41		Published Online First: 2019. doi:10.1177/2050640619889763
42 43		
44	26	Truelove SC Witte LL Cortisone in Illegrative Colitic RM/1055-2:1041 9
45 46	26	Truelove SC, Witts LJ. Cortisone in Ulcerative Colitis. <i>BMJ</i> 1955; 2 :1041–8.
47		doi:10.1136/bmj.2.4947.1041
48 49		
50	27	Van Kerkhove MD, Vandemaele KAH, Shinde V, <i>et al.</i> Risk Factors for Severe
51 52		Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled
53		
54		Analysis. PLoS Med 2011;8:e1001053. doi:10.1371/journal.pmed.1001053
55 56		
57	28	Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on
58 59		plasma SARS-associated Coronavirus RNA concentrations in adult patients. J
60		

Clin Virol 2004;31:304-9. doi:10.1016/j.jcv.2004.07.006

- Arabi YM, Mandourah Y, Al-Hameed F, *et al.* Corticosteroid Therapy for
 Critically III Patients with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med* 2018;**197**:757–67. doi:10.1164/rccm.201706-1172OC
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473–5. doi:10.1016/S0140-6736(20)30317-2
- Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza. Crit Care Med 2020;48:e98–106. doi:10.1097/CCM.000000000004093
- Lewis SR, Pritchard MW, Thomas CM, et al. Pharmacological agents for adults with acute respiratory distress syndrome. *Cochrane Database Syst Rev* Published Online First: 23 July 2019. doi:10.1002/14651858.CD004477.pub3
- The Royal College of Radiologists. Statement on use of CT chest to screen for COVID-19 in pre-operative patients.
 2020.https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-doing/clinical-information/statement-use-ct-chest-screen-covid (accessed 8 May 2020).
- 34 Royal College of Surgeons. Updated Intercollegiate General Surgery Guidance on COVID-19. 2020.https://www.rcseng.ac.uk/coronavirus/joint-guidance-forsurgeons-v2/ (accessed 8 May 2020).
- Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in
 Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.
 Radiology 2020;:200642. doi:10.1148/radiol.2020200642


Gut

- World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected.
 2020.https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus- (accessed 24 May 2020).
 - Shah ED, Farida JP, Siegel CA, et al. Risk for Overall Infection with Anti-TNF and
 Anti-integrin Agents Used in IBD. Inflamm Bowel Dis 2017;23:570–7.
 doi:10.1097/MIB.00000000001049
 - 38 Singh S, Facciorusso A, Dulai PS, *et al.* Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol* 2020;**18**:69-81.e3. doi:10.1016/j.cgh.2019.02.044
 - Zhou L, Xu H. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). Chinese Clin. Trial Regist.
 2020.http://www.chictr.org.cn/showprojen.aspx?proj=49889 (accessed 13 May 2020).
 - Feldmann M, Maini RN, Woody JN, *et al.* Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet* 2020;395:1407–9. doi:10.1016/S0140-6736(20)30858-8
 - Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.
 doi:10.1016/S0140-6736(20)30628-0
 - 42 Fanelli V, Fiorentino M, Cantaluppi V, *et al.* Acute kidney injury in SARS-CoV-2 infected patients. *Crit Care* 2020;**24**:155. doi:10.1186/s13054-020-02872-z
 - 43 Chaparro M, Ordás I, Cabré E, et al. Safety of Thiopurine Therapy in

Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2013;**19**:1404–10. doi:10.1097/MIB.0b013e318281f28f

- Wu C, Chen X, Cai Y, *et al.* Risk Factors Associated With Acute Respiratory
 Distress Syndrome and Death in Patients With Coronavirus Disease 2019
 Pneumonia in Wuhan, China. *JAMA Intern Med* Published Online First: 13
 March 2020. doi:10.1001/jamainternmed.2020.0994
- Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of
 COVID-19: a descriptive and predictive study. Signal Transduct Target Ther
 2020;5:33. doi:10.1038/s41392-020-0148-4
- Sandborn WJ, Su C, Sands BE, *et al.* Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017;**376**:1723–36. doi:10.1056/NEJMoa1606910
- Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. *J Crohn's Colitis* Published Online First: 5 February 2020. doi:10.1093/ecco-jcc/jjaa018
- 48 Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *Preprints.org* Published Online First: 2020. doi:10.20944/preprints202004.0345.v1
- 49 British Thoracic Society. BTS Guidance on Venous Thromboembolic Disease in patients with COVID-19. Br. Thorac. Soc. 2020.https://www.britthoracic.org.uk/document-library/quality-improvement/covid-19/btsguidance-on-venous-thromboembolic-disease-in-patients-with-covid-19/ (accessed 8 May 2020).

4	
5	
4 5 6 7	
6	
7	
8 9 10	
9	
10	
10	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
11 12 13 14 15 16 17 18 19 20	
21	
22	
22	
25	
24	
25	
26	
27	
28	
20	
29	
50	
31	
32	
33	
34	
35	
36	
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	
27	
38 20	
39	
40	
41	
42	
43	
44	
44	
45	
46	
47	
48	
49	
49 50	
51	
51 52	
52	



g.60
 h. Thiopurines: uncertain if SARS-CoV-2 negative and inappropriate if SARS-CoV-2 positive.
 In SARS-CoV-2 negative or SARS-CoV-2 positive patients without pneumonia: consider anti-TNF, vedolizumab or ustekinumab at or soon after discharge.
 In SARS-CoV-2 pneumonia the appropriateness of these agents are uncertain.

1	
2	
3	
4	
5	
6 7	
8	
9	
10	
11	
12	
13	
14	
15	
16 17	
18	
19	
20	
20	
22	
22	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
42	
45 44	
44	

Supplementary Table 1: RAND Panel members

RAND Panellists	Affiliation
Shahida Din*	Western General Hospital, Edinburgh
Alex Kent	King's College Hospital NHS Foundation Trust, London
Richard Pollok*	St Georges University Hospitals NHS Foundation Trust, London
Nick Kennedy^	Royal Devon and Exeter NHS Foundation Trust, Exeter
Robin Dart	Royal Free London NHS Foundation Trust
Daniel Gaya*	Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde
Ailsa Hart^	St Mark's Hospital North West University Healthcare NHS Trust, London
Chris Lamb	Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
Jimmy Limdi	The Pennine Acute Hospitals NHS Trust, Manchester
James Lindsey^	The Royal London Hospital, Barts Health NHS trust, London
Chris Probert	University of Liverpool
Tim Raine^	Cambridge University Hospitals NHS Foundation Trust
Christian Selinger*	Leeds Teaching Hospitals, NHS Trust, Leeds
Shaji Sebastian*^	Hull University Teaching Hospitals NHS Trust
Lisa Younge	St Mark's Hospital, North West University Healthcare NHS Trust, London

*Denotes British Society of Gastroenterology Inflammatory Bowel Disease Section Committee member

^Denotes British Society of Gastroenterology Inflammatory Bowel Disease Clinical Research Group member

Supplementary Table 2. Final Assessment of Statements by RAND Panel: Appropriateness of management in acute severe ulcerative colitis (ASUC) in the context of COVID19

91 Statements	Median	Disagreement Index	Standard Deviation	Category			
Admission All patients admitted with ASUC							
Perform a SARS-CoV-2 swab on admission	8	0.13*	0.51	Appropriate			
Perform a CT chest within 24 hours of admission	4	0.52	1.39	Uncertain			
Perform a CT abdomen, in addition to AXR, within 24 hours of admission	3	0.45	2.09	Inappropriate			
Isolate them in a side room throughout their admission regardless of COVID status	8	0.23	1.21	Appropriate			
Perform a	a flexible sign	noidoscopy					
Within 24 hours of admission in all patients admitted with ASUC (as per BSG guidance)	8	0.00	1.96	Appropriate			
In all patients failing IV corticosteroids who have not had a flexible sigmoidoscopy on admission	9	0.13*	0.64	Appropriate			
In all patients failing intravenous corticosteroid therapy who have already had a flexible sigmoidoscopy on admission	3	0.00	0.88	Inappropriate			
In all patients being referred for colectomy who have not had a flexible sigmoidoscopy on admission, to confirm the diagnosis prior to surgery (excluding patients who have toxic megacolon or perforation)	8	0.23*	0.85	Appropriate			
In all patients being referred for colectomy who have already had a flexible sigmoidoscopy on admission, to assess the degree of ongoing inflammation (excluding patients who have toxic megacolon or perforation)	2	0.16	0.94	Inappropriate			
First	ine medical t	herapy					
Negative swab	and no respi	ratory symptoms	5				
Follow standard BSG guidelines and start intravenous hydrocortisone/methylprednisolone	9	0.10	0.92	Appropriate			

	Gut

1 2 3 4 5	Start IV methylprednisolone 60 mg daily as an outpatient (with daily specialist review, once daily observations and access to x-ray and bloods as required)	3	0.30	2.18	Inappropriate
6 7 8 9	Start budesonide MMX 9 mg or beclometasone 5 mg daily PO (as an inpatient)	1	0.13*	0.74	Inappropriate
10 11 12	Start IV steroids concurrently with infliximab	3	0.13	2.06	Inappropriate
13	Start infliximab without steroids	3	0.33	1.83	Inappropriate
14 15 16	Start ciclosporin monotherapy as a bridge to another therapy	2	0.16	1.41	Inappropriate
17	Start tofacitinib 10 mg bd	2	0.13	1.64	Inappropriate
18 19	Colectomy	1	0.10*	0.74	Inappropriate
20 21 22 23	Discuss with COVID-19 specialist	3	0.16	0.92	Inappropriate
24	Positive swab but no sym	ptoms or sig	ns of COVID-19 p	neumonia	
25	Follow standard BSG guidelines and start				
26 27 28	intravenous hydrocortisone/methylprednisolone	7	0.13	0.80	Appropriate
29 30 31 32 33	Start IV methylprednisolone 60 mg daily as an outpatient (with daily specialist review, once daily observations and access to x-ray and bloods as required)	2	0.29	2.13	Inappropriate
34 35 36 37	Start budesonide MMX 9 mg or beclometasone 5 mg daily PO (as an inpatient)	1	0.10*	0.63	Inappropriate
38 39 40	Start IV steroids concurrently with infliximab	2	0.16	1.58	Inappropriate
41	Start infliximab without steroids	4	0.52	1.94	Uncertain
42 43 44	Start ciclosporin monotherapy as a bridge to another therapy	2	0.16	1.36	Inappropriate
45	Start tofacitinib 10 mg bd	1	0.13	1.10	Inappropriate
46 47	Colectomy	1	0.13*	0.64	Inappropriate
48 49 50 51	Discuss with COVID-19 specialist	7	0.13	1.41	Appropriate
52	Positive swab with symp	otoms or sign	s of COVID-19 pr	neumonia	
53 54 55 56	Follow standard BSG guidelines and start intravenous hydrocortisone/methylprednisolone	6	0.45	1.42	Uncertain
57 58 59 60	Start IV methylprednisolone 60 mg daily as an outpatient (with daily specialist review, once daily observations and access to x-ray and bloods as required)	1	0.00*	0.72	Inappropriate

Start budesonide MMX 9 mg or				
beclometasone 5 mg daily PO (as an inpatient)	1	0.00	2.07	Inappropria
Start IV steroids concurrently with infliximab	2	0.29	1.98	Inappropria
Start infliximab without steroids	5	0.49	1.95	Uncertain
Start ciclosporin monotherapy as a bridge to another therapy	1	0.13	1.39	Inappropria
Start tofacitinib 10 mg bd	1	0.10*	0.49	Inappropria
Colectomy	1	0.13*	0.74	Inappropria
Discuss with COVID-19 specialist	9	0.00*	0.59	Appropriat
	escue Thera	ру		
Repeat a SARS-CoV-2 swab in patients with a negative first swab	7	0.22	2.03	Appropriat
Negative swab a	and no respi	ratory symptoms	5	
Continue intravenous steroids alone	1	0.00*	0.74	Inappropria
Start infliximab and continue steroids	8	0.23*	0.85	Appropriat
Start infliximab and discontinue steroids	4	0.52	1.59	Uncertain
Start intravenous ciclosporin therapy with steroids (unless failed thiopurine)	5	0.95	2.02	Uncertain
Start intravenous ciclosporin and discontinue steroids (unless failed thiopurine)	3	0.22	1.59	Inappropria
Colectomy	3	0.33	1.79	Inappropria
Discuss with COVID-19 specialist	5	0.95	1.85	Uncertain
Positive swab but no sym	ptoms or sig	ns of COVID-19 p	neumonia	
Continue intravenous steroids alone	1	0.00*	0.62	Inappropria
Start infliximab therapy with steroids	7	0.16	1.05	Appropriat
Start infliximab and discontinue steroids	6	0.52	1.59	Uncertain
Start intravenous ciclosporin therapy with steroids (unless failed thiopurine)	3	0.22	1.29	Inappropria
Start intravenous ciclosporin and discontinue steroids (unless failed thiopurine)	3	0.16	1.25	Inappropria
Colectomy	2	0.33	1.74	Inappropria
Discuss with COVID-19 specialist	8	0.26*	0.88	Appropriat
Positive swab with symp	toms or sign	s of COVID-19 pr	neumonia	
Continue intravenous steroids alone	1	0.00	0.92	Inappropria
Start infliximab with steroids	7	0.17	1.06	Appropriat
Start infliximab and discontinue steroids	5	0.52	1.54	Uncertain

Gut

Start intravenous ciclosporin therapy with steroids (unless failed thiopurine)	2	0.27	1.46	Inappropr
Start intravenous ciclosporin and discontinue steroids (unless failed thiopurine)	2	0.29	2.07	Inappropr
Colectomy	2	0.29	1.64	Inappropr
Discuss with COVID-19 specialist	9	0.10*	0.74	Appropri
Contin	uing medical	therapy		
	and no respi	ratory symptoms	5	
Follow standard BSG guidelines for tapering oral steroids over 6-8 weeks	8	0.16	1.06	Appropri
Use an accelerated steroid taper over 4-6 weeks	7	0.13	1.03	Appropri
Use an accelerated steroid taper over fewer than 4 weeks	3	0.30	1.55	Inappropr
Switch to budesonide MMX 9 mg or beclomethasone 5 mg daily PO	3	0.16	0.83	Inappropr
Taper steroids and follow standard BSG guidelines initiating thiopurine therapy at or soon after discharge	4	0.45	1.77	Uncerta
Taper steroids and initiate anti-TNF therapy at or soon after discharge	7	0.00	0.64	Appropri
Taper steroids and initiate ustekinumab at or soon after discharge	7	0.00	1.76	Appropri
Taper steroids and initiate vedolizumab at or soon after discharge	7	0.22	1.72	Appropri
Taper steroids and initiate tofacitinib at or soon after discharge	4	0.86	1.92	Uncerta
Continue prophylactic anticoagulation for a period after discharge	5	0.95	1.98	Uncerta
Positive swab but no sym	ptoms or sig	ns of COVID-19 p	neumonia	
Follow standard BSG guidelines for tapering oral steroids over 6-8 weeks	7	0.45	1.58	Appropri
Use an accelerated steroid taper over 4-6 weeks	7	0.16	0.70	Appropri
Use an accelerated steroid taper over fewer than 4 weeks	3	0.45	1.82	Inappropr
Switch to budesonide MMX 9 mg or beclomethasone 5 mg daily PO	3	0.16	1.35	Inappropr
Taper steroids and follow standard BSG guidelines initiating thiopurine therapy at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	3	0.16	1.49	Inappropr

1 2 3 4 5	Taper steroids and initiate anti-TNF therapy at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	7	0.22	1.21	Appropriate
6 7 8 9 10 11	Taper steroids and initiate ustekinumab at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	6	0.52	1.71	Uncertain
12 13 14 15 16	Taper steroids and initiate vedolizumab at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	6	0.52	1.73	Uncertain
17 18 19 20 21	Taper steroids and initiate tofacitinib at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	3	0.00	0.83	Inappropriate
22 23	Continue prophylactic anticoagulation for a period after discharge	7	0.00	1.31	Appropriate
24 25	Positive swab with symp	toms or sign	s of COVID-19 pr	neumonia	
26 27 28	Follow standard BSG guidelines for tapering oral steroids over 6-8 weeks	6	0.84	1.92	Uncertain
29 30	Use an accelerated steroid over 4-6 weeks	7	0.13	0.88	Appropriate
31 32 33	Use an accelerated steroid taper over fewer than 4 weeks	4	0.52	2.15	Uncertain
34 35 36	Switch to budesonide MMX 9 mg or beclomethasone 5 mg daily PO	2	0.27	1.55	Inappropriate
37 38 39 40 41 42	Taper steroids and follow standard BSG guidelines initiating thiopurine therapy at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	3	0.16	1.29	Inappropriate
43 44 45 46 47	Taper steroids and initiate anti-TNF therapy at or soon after discharge (but within the period of potential ongoing SARS-CoV2 infection)	6	0.45	1.56	Uncertain
48 49 50 51 52 53	Taper steroids and initiate ustekinumab at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	6	0.49	1.94	Uncertain
53 54 55 56 57 58	Taper steroids and initiate vedolizumab at or soon after discharge (but within the period of potential ongoing SARS-CoV-2 infection)	5	0.52	1.68	Uncertain
59 60	Taper steroids and initiate tofacitinib at or soon after discharge (but within the period of potential ongoing SARS-CoV-2	3	0.27	1.30	Inappropriate

1 2 3 4	infection)				
5 6 7	Continue prophylactic anticoagulation for a period after discharge	8	0.13*	0.83	Appropriate
8		Surgery			
9 10 11 12	In patients with a SARS-CoV-2 positive swab who have failed medical therapy, surgery should be delayed	3	0.17	1.29	Inappropriate
13 14 15	Patients with a negative swab on admission should have a repeat swab	8	0.16	1.51	Appropriate
16 17 18 19 20	Patients should have a CT chest prior to surgery regardless of swab status, respiratory symptoms examination findings and observations	8	0.16	0.92	Appropriate

* Denotes questions where all panelists voted the same appropriateness category as the final outcome category (i.e. level of appropriateness was agreed unanimously) nateness mar ru

Supplementary Table 3: Conflicts of interests declared by authors of manuscript Adaptation of British Society of Gastroenterology guidelines on the management of acute severe ulcerative colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

Q1: Do you, your partner (if applicable) or any member of your immediate family have any commercial interest (including personal shares, sponsorship or paid consultancy work) in any companies that are, or could be, involved in the above-named guideline?Q2: Does your department or unit receive financial support from any commercial organisations that are, or could be, involved in the above-named guideline?

Q3: Are you a consultant to or a member of any national body, charity or pressure group whose work is related to the above-named guideline?

Q4: Do you receive editorial fees for commissioned articles for publication (in any format) or are you paid for editorial work for any publication related to the above-named guideline?

Q5: Do you or your department hold a patent (existing or pending) related to the above-named guideline?

	Preferred name or middle initial	Family name	Q1 response	Q2 response	Q3 response	Q4 response	Q5 response
Shahida		Din	Speaker fees/educational support AbbVie, Dr Falk, Takeda		BSG IBD Committee Member 2019-2022 BSG Member 2010	No	No
Alexandra	J	Kent	Consultancy to Abbvie, and speaker fees with Pfizer, Janssen and Takeda.	No	No	No	No
Richard		Pollok			BSG IBD Section Member: BSG is an organisation for Gastroenterologists	No	No
Susanna		Meade	No	No	No	No	No
Nick	А	Kennedy	Janssen: Speaker fees, from 2019-	AbbVie: Research support,	ECCO: Member, from 2011-	No	No

				from 2013-2020. Celltrion: Research support, from 2015- 2020. Celgene: Research support. From 2018-2020			
Ian		Arnott	No	No	BSG IBD section committee chair	No	No
R	Mark	Beattie	No	No	No	No	No
Felix		Chua	No	No	No	No	No
Rachel		Cooney	No	No	No	No	No
Robin	J	Dart	Takeda: Consultancy, from April 2019 to May 2019	No	No	No	No
James		Galloway	No	No	No	No	No
Daniel	R	Gaya	Abbvie, Ferring, Vifor, Janssen, Pfizer: Speaker fees &/or travel grants, from 2015 to 2020	No	BSG IBD Committee: Secretary from 2019 to 2022	No	No
Subrata		Ghosh		AbbVie: Research grant, from 2019 to 2020	No	No	No
Mark		Griffiths	No	No	No	No	No
Laura		Hancock	No	No	No	No	No
Richard		Hansen	4D Pharma: Consultancy fees and meeting expenses, from 2014 to 2019. Nutricia: Consultancy fees and meeting expenses, from 2014 to 2019	No	CiCRA: Honorary Medical Director from March 2017 to present	No	No
Ailsa		Hart	AbbVie, Celltrion, Falk, Ferring, Janssen, MSD,	No	Crohn's and Colitis UK: Scientific	No	No

Page !	52 of	92
--------	-------	----

			Napp Pharmaceuticals, Pfizer, Shire and Takeda: Advisory Boards Lecture Fees. Within last 5 years		Research Committee, last 5 years		
Chris	A	Lamb	Janssen, Takeda, Abbvie, AstraZeneca, Eli Lilly, Orion, Pfizer,Roche, Sanofi Aventis, Ferring UCB and Biogen: Research support and/or fees for development and delivery of non-promotional education, from October 2019 to present. Genentech Inc: Research support, from October 2012 to present	See Q1 ,	British Society of Gastroenterology: IBD Section Committee Member, from June 2018 to present British Society of Gastroenterology: Society member, from 2008 to present	No	No
Charlie	W	Lees	Takeda, Abbvie, Gilead, Pfizer, GSK, Janssen, Vifor, and Ferring: Consultancy and Lecture fees, from 2018 - 2021	Gilead, Ferring and Janssen: Unrestricted research grant, from 2019-2021	BSG IBD Clinical Research Group Chair	No	No
Jimmy	К	Limdi	AbbVie: Consultancy and speaker fees, from 2014-2019. Janssen: Consultancy and speaker fees, from 2017 to present.	Takeda: Consultancy and speaker fees, from 2018 to present. Research support.	MSD: Speaker fees, from Jan 2020 to Jan 2020 only. Pfizer: Speaker fees, from June 2019-present	No	No
ames	0	Lindsey	Abbvie, Ferring, GSK, Janssen, Takeda, Pfizer, Napp, Shire, Celltrion, Celgene and Gilead: I have received honoraria for advisory Boards and for lectures from January 2018 to March 2020	Abbvie, Gilead, (Jan 2020 ongoing), Takeda (Jan 2017 to Jan 2020), Abbvie (Jan 2019 ongoing): Research grant support for investigator Led translational research. UK National led for Upadacitinib and Risankizumab phase III program		No	No
Charlie	D	Murray	No	No	No	No	No
Kamal		Patel	Abbvie, Janssen, Takeda, T, illots	No	No	No	No

Gut

		Dr Falk, Ferring: Honoraria received for educational meetings and speaker fees from all listed companies. Advisory board fees from Janssen and Abbvie. 2017 to date				
Nick	Powell	BMS: Consultant, from 2019 to current. AbbVie: Consultant, from 2018 to current. Celgene: Consultant, from 2018 to current. Allergan: Consultant, from 2018 to current. Eli-Lilly: Consultant, from 2018 to current	Takeda: Honoraria for talks, from 2018 to current. Allergan: Honoraria for talks, from 2018 to current. Janssen: Honoraria for talks, from 2018 to current. Tillotts: Honoraria for talks, from 2018 to current. BMS: Honoraria for talks, from 2018 to current	No	No	No
Chris	Probert	My pharma work (within last 2 years) is in relation to disease areas unrelated to IBD	No	Crohn's & Colitis UK: Former committee member, now Research Panel member From 2009 To 2023. BSG: Former Section Lead, Council Member and Trustee From 2011 to 2018	No	No
Tim	Raine	Abbvie, BMS, Celgene, Ferring, Gilead, GSK, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda and UCB: Research/educational grants and/or speaker/consultation fees, from 2017 to present	Unrestricted educational grant from Abbvie	No	No	No
Christian P	Selinger	Dr Falk: Speaker from 2015	Janssen: Unrestricted	BSG IBD section committee	No	No

			to ongoing. AbbVie: Speaker and consultancy from 2015 to ongoing. Takeda: Speaker and consultancy from 2015 to ongoing. Fresenius Kabi: Consultancy from 2019 to ongoing. Janssen: Speaker and consultancy from 2017 to ongoing. Pfizer: Speaker from 2019 to ongoing	research grants from 2019 to ongoing. AbbVie: Unrestricted research grants from 2015 to ongoing. Takeda: Unrestricted research grants from 2017 to ongoing	member.		
Shaji		Sebastian	No	No	No	No	No
Phil	J	Smith	No		CICRA, Guts UK and IBD Passport Trustee: I am a trustee of these Gastro/IBD charities. BSG IBD section committee member	No	No
Phil		Tozer	No			No	No
Andrew		Ustianowski	Served as a speaker for UCB, Biogen	Our Research Unit has participated in study programmes with: Abbvie, Alios, BMS, Gilead, Janssen, MSD, Roche, ViiV	No	No	No
Lisa		Younge	No	No	No	No	No
Mark	А	Samaan	Served as a speaker, a consultant and/or an advisory board member for Sandoz, Janssen, Takeda, MSD, Falk, Samsung Bioepis.	No	No	No	No
Peter	М	Irving	AbbVie, Celgene, Falk Pharma, Ferring MSD, Janssen, Pfizer, Takeda, Tillotts, Sandoz, Shire, Warner Chilcott: Speaking/education, intermittent -	No	No	No	No

last 3 years. MSD, Pfizer, Takeda:		
Research, intermittent - last 3		
years. AbbVie, Arena, Genentech,		
Gilead, Hospira, Janssen, Lilly, MSD,		
Pfizer, Pharmacosmos, Prometheus,		
🗋 🕖 👝 Roche, Sandoz, Samsung Bioepis,		
Takeda, Topivert,VH2, Vifor Pharma:		
Advisory fees, intermittent - last		
3 years		
Advisory fees, intermittent - last 3 years		

Gut

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe ulcerative colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

Authors

- Shahida Din (Department of Gastroenterology, Western General Hospital, Edinburgh, UK)*
- Alexandra Kent (Department of Gastroenterology, King's College Hospital NHS Foundation Trust, London, UK) *
- 3. Richard C Pollok (Department of Gastroenterology, St Georges University Hospitals NHS Foundation Trust, London, UK) *
- Susanna Meade (Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK) *
- 5. Nicholas A Kennedy (Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK)
- Ian Arnott (Department of Gastroenterology, Western General Hospital, Edinburgh, UK)
- 7. R Mark Beattie (Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK)
- Felix Chua (Interstitial Lung Disease Unit, Department of Respiratory Medicine, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London)
- 9. Rachel Cooney (Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, UK)

Gut

2	
3 4	10. Robin J. Dart (Department of Gastroenterology, Royal Free London NHS
5	Foundation Trust, London, UK)
6 7	11. James Galloway (Department of Rheumatology, King's College Hospital NHS
8	Foundation Trust, London, UK)
9 10	
11	12. Daniel R Gaya (Gastroenterology Unit, Glasgow Royal Infirmary, Castle Street,
12 13	Glasgow, UK)
14	13. Subrata Ghosh (Queen Elizabeth Hospital Birmingham NHS Foundation Trust,
15 16	Birmingham, UK)
17	
18 19	14. Mark Griffiths (Peri-operative medicine, St Bartholomew's Hospital, London,
20	UK)
21 22	15. Laura Hancock (Manchester University Foundation Trust, Manchester, UK)
23 24	16. Richard Hansen (Glasgow Royal Infirmary, Glasgow, UK and University of
25	Glasgow, Glasgow, UK)
26 27	
28	17. Ailsa Hart (IBD Unit, St Mark's Hospital, London, UK)
29 30	18. Christopher A Lamb (Department of Gastroenterology, Newcastle upon Tyne
31	Hospitals NHS Foundation Trust, Newcastle, UK)
32 33	19. Charlie W Lees (Department of Gastroenterology, Western General Hospital,
34	Edinburgh, UK)
35 36	
37	20. Jimmy K Limdi (Department of Gastroenterology, The Pennine Acute
38 39	Hospitals NHS Trust, Manchester, UK)
40	21. James O Lindsay (Department of Gastroenterology, The Royal London
41 42	Hospital, Barts Health NHS Trust, London, UK)
43	22. Charlie <u>D</u> Murray (Department of Gastroenterology, Royal Free London NHS
44 45	
46	Foundation Trust, London, UK)
47 48	23. Kamal Patel (Department of Gastroenterology, St Georges University
49	Hospitals NHS Foundation Trust, London, UK)
50 51	24. Nick Powell (Department of Gastroenterology, Imperial College Healthcare
52	
53 54	NHS Trust, London, UK)
55	25. Chris Probert (Gastroenterology Research Unit, Department of Cellular and
56 57	Molecular Physiology, Institute of Translational Medicine, University of
58	Liverpool, Liverpool, UK)
59 60	

- 26. Tim Raine (Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK)
- 27. Christian Selinger (Department of Gastroenterology, Leeds Teaching Hospitals, NHS Trust, Leeds, UK)
- 28. Shaji Sebastian (IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK)
- 29. Philip J Smith (Department of Gastroenterology, Royal Liverpool Hospital, Liverpool, UK)
- 30. Phil Tozer (IBD Unit, St Mark's Hospital, London, UK)
- 31. Andrew Ustianowski (Dept of Infectious Disease, North Manchester General Hospital, Manchester, UK)
- 32. Lisa Younge (IBD Unit, St Mark's Hospital, London UK)
- 33. Mark A Samaan (Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London UK)
- 34. Peter M Irving (School of Immunology and Microbial Sciences, King's College London, UK)
- * Joint first authors

Corresponding Author:

Peter M Irving, College House, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK.

E: Peter.irving@gstt.nhs.uk

<u>T: +44 207 188 2491</u>

F: +44 207 188 2484

Key words: Ulcerative colitis, clinical decision making, IBD clinical

Abbreviations:

Acute severe ulcerative colitis (ASUC)

Novel coronavirus 2019 (COVID-19)

British Society of Gastroenterology (BSG)

RAND/UCLA (Research and Development/University of California, Los Angeles)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Disagreement index (DI)

Inflammatory bowel disease (IBD)

World Health Organisation (WHO)

<u>Physician response to disease flares and patient adaptation in response to events in</u> <u>inflammatory bowel disease during the COVID-19 pandemic (PREPARE IBD)</u>

5-aminosalicylic acid (5-ASA)

Computed tomography (CT)

Anti-tumour necrosis factor (anti-TNF)

International Organisation For the Study of Inflammatory Bowel Disease (IOIBD)

Middle Eastern Respiratory Syndrome (MERS)

Chest x-ray (CXR)

Venous thromboembolism (VTE)

.h. .i.matrix). Verd count: 4:08 Clinical Research Group (CRG)

https://mc.manuscriptcentral.com/gut

Abstract

Objective

Management of acute severe ulcerative colitis (ASUC) during the <u>novel coronavirus</u> <u>2019 (COVID-19)</u> pandemic presents significant dilemmas. We aimed to provide <u>COVID-19-specific</u> guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point.

Design

We convened a RAND appropriateness panel comprising 14 gastroenterologists and an IBD nurse consultant supplemented by surgical and COVID-19 experts. Panellists <u>completed a survey ratingrated</u> the appropriateness of interventions for ASUC in the context of <u>severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)</u> infection. Median scores and disagreement index (DI) were calculated. Results were <u>presented</u> and discussed at a moderated meeting prior to a second survey.

Results

Panellists recommended that patients with ASUC should be isolated throughout their hospital stay and should have a SARS-CoV-2 swab performed on admission. Patients with a positive swab should be discussed with COVID-19 specialists.

As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was their use deemed uncertain. In patients requiring rescue therapy, infliximab with continuing steroids was recommended. Delaying colectomy because of COVID-19 was deemed inappropriate.

Steroid tapering as per BSG guidance, was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4-6-week taper was preferred. Post-

ASUC maintenance therapy was dependent on SARS-CoV-2 status but, in general, biologics were more likely to be deemed appropriate than azathioprine or tofacitinib. Panellists deemed prophylactic anticoagulation post-discharge to be appropriate in patients with a positive SARS-CoV-2 swab.

Gut

Conclusion

.i. .v2 s. We have suggested COVID-19-specific adaptations to the BSG ASUC guideline using a RAND Panel.

Significance of the Study

What is already known on this subject?

- The BSG has published evidence-based guidelines for management of patients with ASUC, but it is unknown whether these are appropriate in the setting of SARS-CoV-2.
- Currently there are limited data to inform clinicians in this area and there is no published guidance for the management of ASUC in the setting of the COVID-19 pandemic.

What are the new findings?

- The current BSG IBD guidelines provide a management pathway which remains largely appropriate during the COVID-19 pandemic.
- However, some treatment options were deemed uncertain or inappropriate in patients with established COVID-19 pneumonia.
- It is appropriate to involve COVID-19 specialists in decision-making for ASUC patients who are SARS-CoV-2 positive.
- Steroid tapering as per BSG guidance, was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4-6-week taper was preferred.
- Prophylactic anticoagulation post-discharge is appropriate in patients with a positive SARS-CoV-2 swab

How might it impact on clinical practice in the foreseeable future?

This paper summarises available evidence and provides expert opinion for the appropriate management of patients with ASUC during the COVID-19 pandemic. It also highlights areas of uncertainty which may help direct areas of future research.

Gut

Contributors

All authors approved the final version. Study concept and design: SD, RP, AK, MS, PI. Development of questionnaire: SD, RP, AK, SM, PI, MS, NK. Data Analysis: PI, MS, SM. Interpretation of data and drafting of manuscript: SD, RP, AK, SM, MS, NK, PI. Panellists, experts and moderators: SD, AK, RP, SM, NK, JOL, CAL, JKL, CP, CS, SS, DRG, TR, RD, AH, LY, CWL, IA, FC, JG, AU, MG, PT, LH, MS, SM, PI Contributions to literature review and critical revision of the manuscript for important intellectual content: All authors

ORCID iDs

SD 0000-0003-2855-3400

AK 0000-0003-0577-6177

RP 0000-0001-6452-6763

SM 0000-0002-8283-6148

NK 0000-0003-4368-1961

IA 0000-0003-3352-925

MB 0000-0003-4721-0577

FC 0000-0001-7845-0173

1 2 3 4 5	RC 0000-0003-3710-157X
6 7 8	RD 0000-0003-3470-8210
9 10 11 12	JG 0000-0002-1230-2781
13 14 15	DRG 0000-0003-1942-7568
16 17 18	SG 0000-0002-1713-7797
19 20 21 22	MG 0000-0002-1615-1896
23 24 25	LH 0000-0002-8399-6646
26 27 28 29	RH 0000-0002-3944-6646
30 31 32	AH 0000-0002-7141-6076
33 34 35 36	CAL 0000-0002-7271-4956
37 38 39	CWL 0000-0002-0732-8215
40 41 42 43	JKL 0000-0002-1039-6251
44 45 46 47	JOL 0000-0003-3353-9590
48 49 50	KP 0000-0003-2611-4260
51 52 53	NP 0000-0003-3231-6950
54 55 56 57 58	CM 0000-0001-6736-1546
58 59 60	CP 0000-0003-0477-6714

TR 0000-0002-5855-9873

CS 0000-0003-2022-5859

SS 0000-0002-3670-6545

PJS 0000-0003-1568-3978

PT 0000-0002-2532-7267

LY 0000-0002-3436-9696

review only MAS 0000-0002-4057-9200

PMI 0000-0003-0972-8148

Gut

Introduction

The novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was first reported in December 2019 and its spread led to the declaration of a pandemic by the World Health Organisation (WHO) on 11th March 2020. Infection varies in severity from asymptomatic carriage to an acute respiratory illness which, at its most severe, results in acute respiratory distress syndrome with hyperinflammation and cytokine storm syndrome.[1] By mid-May 2020, there have been nearly 5 million cases reported worldwide with over 300,000 deaths.[2] Risk factors associated with more severe coronavirus disease 2019 (COVID-19) include older age, male sex, hypertension, cardiovascular disease, respiratory disease, diabetes, renal failure, and ethnicity.[3] Neither an effective medical therapy nor a vaccine has yet been described, although numerous candidates are under evaluation.

Acute severe ulcerative colitis (ASUC) occurs in up to 25% of patients with UC and is associated with a mortality of approximately 1%.[4,5] The management of ASUC is particularly challenging in the context of SARS-CoV-2 as the typical presenting features of ASUC, namely diarrhoea with raised inflammatory markers, often in association with a fever, may mimic those of COVID-19. ASUC is managed with high dose parenteral corticosteroids, progressing to rescue therapy and/or surgery in those who fail to respond adequately.[6] The safety of all of these interventions in the context of COVID-19 infection is unclear. For example, there are concerns that corticosteroids may increase the risk of acquiring SARS-CoV-2 infection and/or worsen the severity of COVID-19 disease.[7] In addition, the commonly used rescue therapies, infliximab and ciclosporin are associated with an increased risk of infection, particularly if used in combination with immunomodulators such as thiopurines, or steroids.[8] Finally, individuals in whom corticosteroids and rescue therapy fail require urgent colectomy which is associated with high morbidity and mortality in patients infected with SARS-CoV-2.[9] However, withholding treatment in ASUC is clearly not an option in view of the high mortality (in excess of 20%) associated with such an approach.[10]

Whilst national and international registries continue to collate data regarding IBD patients with COVID-19, very few cases relate to the management of ASUC. The PREPARE IBD study (www.prepareibd.org) is collecting data from patients with inflammatory bowel disease (IBD) who are admitted to hospital during the pandemic, as well as from those who develop confirmed or suspected SARS-CoV-2 infection. As of 8th May 2020, 19 patients with severe active UC including four with suspected or confirmed COVID-19 had been identified (personal communication, manuscript submitted). The Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-IBD registry (https://covidibd.org/) is collating data on IBD patients with confirmed coronavirus, with 1074 patients included to date, the majority of whom have Crohn's disease; details of how many in the cohort have ASUC are not yet available.[11] Finally, in case series from Italy and Spain, 4 of 79 and 1 of 40 patients respectively had COVID-19 in conjunction with ASUC [12,13] (the number of ASUC patients in the Italian case series was provided on request from authors).

Treatment of ASUC during the COVID-19 pandemic presents substantial management dilemmas in the absence of a high-quality evidence base to guide clinicians. We therefore aimed to address this deficit of informed guidance by convening a RAND appropriateness panel. Current BSG guidelines were used as a reference point to highlight differences to current management.[6]

Methods

Study Overview

The RAND/UCLA (University of California, Los Angeles) appropriateness method uses a modified Delphi panel approach and combines expert opinion with the best available evidence to determine the appropriateness of specific practices in certain clinical situations.[14] It is particularly useful in areas of uncertainty in which evidence is insufficient to guide day-to-day clinical practice, such as in the COVID-19 pandemic.[15]

Gut

The aim of this RAND panel was to provide clarity on the management of ASUC, as defined by Truelove and Witts criteria, in the context of the COVID-19 pandemic.[10] The panel sought to identify areas where it was appropriate to deviate from current BSG ASUC guidance and consider alternative strategies.

We assembled a 15-person panel comprising representatives from the BSG IBD Section Committee, the BSG IBD Clinical Research Group (CRG) and other gastroenterologists, each from different IBD centres across the UK, as well as an IBD nurse consultant (supplementary Table 1). A web-based questionnaire was created and iteratively improved before being completed by all panellists prior to a moderated online meeting. We circulated a list of relevant publications with the questionnaire, comprising the current BSG guidelines on the management of ASUC[6] along with up to date publications about COVID-19 in general and specifically in relation to IBD. Due to the rapid growth of available data, the panel used a range of instant messaging services to disseminate publications that were not available at the time of the initial literature review.

Panellists rated the appropriateness of management options at five different time points during the course of admission for ASUC (admission, first line therapy, rescue therapy, continued medical therapy and surgery) in the context of absence of, or varying severity of SARS-CoV-2 infection. They were asked to grade the appropriateness of specific interventions on a scale of 1-9 (where 1-3 is inappropriate, 4-6 is uncertain and 7-9 is appropriate). The responses were summarised and anonymised before being presented at a virtual meeting in May 2020 with the aim of allowing discussion which ensured a common understanding of the questions and which focussed on areas of disagreement, without trying to force consensus. Also present at the meeting were non-voting specialists who provided expert opinion with regards to IBD surgery (PT, LH), rheumatology (JG), intensive care (MG), respiratory medicine (FC) and infectious diseases (AU). In practice, several specialities may provide expert opinion in COVID-19 management, including intensivists, respiratory physicians and infectious disease physicians. We, therefore, used the encompassing term "COVID-19 specialist" to represent this group. Finally, the Chairs of the BSG IBD

Section Committee (IA) and the BSG IBD Clinical Research Group (CL) were also present. The moderators (PI, MS) neither expressed opinions on management nor voted, but were experts both in RAND panels and in the management of IBD. After the meeting, a second online survey comprising 91 questions, which had been slightly modified from the initial questionnaire following discussion at the meeting, was circulated for completion.

Several assumptions were made for clarity. First, patients were assumed to have a confirmed diagnosis of UC with intercurrent gastrointestinal infection having been excluded. Second, if this was not an index presentation, patients were assumed to have received optimised 5-aminosalicylic acid (5-ASA) therapy prior to admission and were also presumed to be biologic-naïve. In addition, where ciclosporin was suggested as an option, it was assumed that the patient was thiopurine-naïve. Third, other than those areas addressed in the survey, the management of ASUC was assumed to be in line with BSG guidance.[6] Finally, where steroid weaning or discontinuation was considered, it was assumed that patients could safely stop steroids without the risk of Addisonian crisis.

In addition, in the section about first line medical therapy, panellists assumed patients were not steroid refractory. For the rescue therapy section, patients were assumed to have ongoing acute severe colitis despite 3 days of intravenous corticosteroid therapy and had reached standard criteria for rescue therapy.[16] For the continuing medical therapy section, patients were assumed to have responded to intravenous corticosteroids sufficiently to switch to oral prednisolone and were ready to be discharged from hospital. Lastly, as per RAND methodology, respondents were advised to make decisions without considering local availability of treatments or cost.

Analysis

For each scenario, median scores were calculated with a score of <3.5 being considered inappropriate, \geq 3.5 but <6.5 uncertain, and \geq 6.5 appropriate. We used the validated RAND disagreement index (DI) to define disagreement amongst panellists

using the equation outlined below.[14] A $DI \ge 1$ denotes disagreement. Any scenario in which disagreement was found was scored as uncertain, regardless of the median score.

$$DI = \frac{70\% ile - 30\% ile}{2.35 + \left(1.5 \times abs\left(5 - \frac{70\% ile + 30\% ile}{2}\right)\right)}$$

Results

Overall Results

Of the 91 clinical scenarios, panellists rated 28 as appropriate, 19 as uncertain and 44 as inappropriate. After the second round of voting, agreement was present for all scenarios (DI<1). The key findings are summarised below and their relationship to current BSG guidance is highlighted in figure 1. A detailed list of all scenarios, complete with median score, appropriateness rating and DI can be found in supplementary Table 2.

Indications for investigations, inpatient isolation and specialist referral (Table 1)

The panellists agreed that all patients admitted to hospital with ASUC should have a SARS-CoV-2 swab performed on admission. If the result was negative it was deemed appropriate to repeat the swab at the point of requiring rescue therapy and/or surgery to exclude subclinical infection. It was also considered appropriate to isolate all patients throughout their hospital stay, irrespective of their COVID-19 status.

It was rated appropriate to perform a flexible sigmoidoscopy within 24 hours of admission. If a patient had not had a flexible sigmoidoscopy on admission, it was considered appropriate that one should be performed prior to rescue therapy or colectomy. Repeating this test at these timepoints was deemed unnecessary in patients who had already had a flexible sigmoidoscopy performed.

Routine computed tomography (CT) scanning of the abdomen/pelvis on admission (in addition to abdominal X-ray) was deemed inappropriate. However, the appropriateness of routine chest CT on admission was rated as uncertain. The one scenario in which a CT scan of the chest was felt to be appropriate for all patients irrespective of COVID-19 status was in the context of patients requiring colectomy.

Throughout the scenarios, the panellists considered the appropriateness of discussion with COVID-19 specialists. In patients without symptoms or signs of COVID-19 and Jina, rescue tr. a positive swa. with a negative swab this was deemed inappropriate if receiving first line therapy but uncertain in patients requiring rescue therapy. However, it was considered appropriate in all patients with a positive swab, irrespective of the presence of symptoms or signs of COVID-19.

Page 73 of 92

1

2	
3	
4	
5	
6 7	
8 9	
10	
11	
12	
13	
14	
15	
16 17	
1/	
18 19	
20 21	
21	
22 23	
23 24	
24 25	
25	
26 27	
27	
20 29	
30	
31	
32	
33	
34	
36	
35 36 37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

	On admission	Prior to Rescue therapy	Prior to colectomy
Inpatient Isolation		All patients	
SARS-CoV-2 swab	Perform in all patients	Repeat swab if initial swab negative	Repeat swab if initial swab negative
Flexible	≤24h admission	If not performed	If not performed
sigmoidoscopy		If already performed	If already performed
CT chest	Perform in all patients		Perform in all patients
CT abdomen & pelvis	Perform in all patients		

Table 1. Appropriateness of patient isolation and investigation in patients admitted with acute severe ulcerative colitis in the context of the COVID-19 pandemic. (Green is considered appropriate, yellow uncertain and red inappropriate).

As per BSG guidance, intravenous hydrocortisone, 100mg, four times per day (or equivalent) was rated appropriate as the initial management of patients presenting with ASUC in the absence of symptoms and signs of COVID-19 pneumonia. In patients with COVID-19 pneumonia, use of hydrocortisone was deemed uncertain. Other possible treatments (poorly bioavailable oral steroids e.g. budesonide multi-matrix (MMX) and beclometasone modified release, infliximab either with or without steroids, ciclosporin or tofacitinib) were considered inappropriate. The exception was infliximab (without steroids) which was considered uncertain in patients with a positive swab for SARS-CoV-2, either with or without signs of COVID-pneumonia. Ambulatory outpatient management with daily intravenous methylprednisolone was rated as inappropriate in all patients with ASUC regardless of SARS-CoV-2 status, as .ton, .s toxic me. was management by immediate colectomy unless complications mandating emergency surgery were present such as toxic megacolon, perforation or severe haemorrhage.

Gut

https://mc.manuscriptcentral.com/gut

		F	First line medical therap	y	
Negative COVID swab WITHOUT	*Inpatient IV steroids	Poorly bioavailable steroids	IFX alone	Tofacitinib	^Discussion with COVID-19 specialist
respiratory symptoms	**Ambulatory IV steroids	IV steroids* + IFX	Ciclosporin	Colectomy	
Positive COVID swab WITHOUT respiratory	*Inpatient IV steroids	Poorly bioavailable steroids	IFX alone	Tofacitinib	^Discussion with COVID-19 specialist
symptoms or signs of COVID pneumonia	**Ambulatory IV steroids	IV steroids* + IFX	Ciclosporin	Colectomy	
Positive COVID swab WITH symptoms or signs of COVID pneumonia	*Inpatient IV steroids	Poorly bioavailable steroids	IFX alone	Tofacitinib	^Discussion with COVID-19 specialist
	**Ambulatory IV steroids	IV steroids* + IFX	Ciclosporin	Colectomy	

Table 2. Appropriateness of treatment options in acute severe ulcerative colitis in the context of the COVID-19 pandemic: First line medical therapy. (Green is considered appropriate, yellow uncertain and red inappropriate). *Steroids, intravenous (IV) hydrocortisone 100mg QDS or IV methylprednisolone 60mg daily as an inpatient; **IV Methylprednisolone 60mg daily as an outpatient; *Budesonide MMX 9 mg/beclometasone 5 mg OD PO as an inpatient; IFX, Infliximab (either 5mg/kg or 10mg/kg); ^Discussion with appropriate COVID-19 specialist as per local availability.

Rescue therapy (Table 3)

In patients meeting criteria for escalation of management at day 3, it was considered inappropriate to avoid rescue therapy by continuing monotherapy with intravenous corticosteroids, irrespective of COVID status. Instead, the panellists deemed that following standard BSG guidance by initiating infliximab and continuing steroids was appropriate, whereas treatment with infliximab in conjunction with immediate steroid withdrawal was deemed uncertain. The BSG guidelines also recommend ciclosporin as an alternative rescue therapy. However, the RAND panel voted that ciclosporin, either with or without ongoing steroids, was inappropriate in all scenarios other than in patients with a negative SARS-CoV-2 swab in whom it was rated uncertain. Finally, colectomy without rescue therapy was deemed inappropriate in all of the scenarios considered by the panel. However, once colectomy became necessary, for example where rescue therapy had failed or when complications had occurred, it was deemed inappropriate to delay surgery, even in patients with COVID-19 pneumonia.

Gut

or peries of

	Rescue therapy			Failure of Rescue Therapy	
Negative COVID swab WITHOUT respiratory symptoms	Continue IV steroids alone	IFX + steroids	IV ciclosporin + steroids	Colectomy	Delau surgera
		IFX, stop steroids	IV ciclosporin, stop steroids	^Discussion with COVID-19 specialist	Delay surgery
Positive COVID swab WITHOUT respiratory symptoms or signs of COVID pneumonia	Continue IV steroids alone	IFX + steroids	IV ciclosporin + steroids	Colectomy	Delay surgery
		IFX, stop steroids	IV ciclosporin, stop steroids	^Discussion with COVID-19 specialist	
Positive COVID swab WITH symptoms or signs of COVID pneumonia	Continue IV steroids alone	IFX + steroids	IV ciclosporin + steroids	Colectomy	Dolou surgers
		IFX, stop steroids	IV ciclosporin, stop steroids	^Discussion with COVID-19 specialist	Delay surgery

Table 3. Appropriateness of treatment options in acute severe ulcerative colitis in the context of the COVID-19 pandemic: Rescue therapy. (Green is considered appropriate, yellow uncertain and red inappropriate). Steroids, Intravenous (IV) hydrocortisone 100mg QDS or IV methylprednisolone 60mg daily as an inpatient; IFX: Infliximab (either 5mg/kg or 10mg/kg); ^Discussion with appropriate COVID-19 specialist as per local availability.

Continuing medical therapy (Table 4)

The ongoing management of patients who had responded to intravenous corticosteroids and were ready for discharge on oral steroids was also considered. In patients with a negative SARS-CoV-2 swab, or with a positive swab but without signs or symptoms of pneumonia, steroid tapering over 6-8 weeks as per BSG guidance was deemed appropriate. However, in patients with COVID-19 pneumonia it was rated uncertain. Accelerated steroid withdrawal over 4-6 weeks was rated appropriate regardless of <u>COVID-19</u> status. More rapid withdrawal over 4 weeks was deemed inappropriate except in patients with <u>COVID-19</u> pneumonia, in whom it was rated uncertain. The use of poorly bioavailable oral steroids as an alternative to a standard steroid taper was rated as inappropriate in all scenarios

Initiation of additional therapy prior to, or soon after discharge to prevent relapse was also considered. Following BSG guidance by initiating a thiopurine was rated uncertain in SARS-CoV-2 swab-negative patients, and inappropriate in swab-positive patients. Use of biological therapy (anti-tumour necrosis factor (TNF), ustekinumab or vedolizumab) was deemed appropriate in swab-negative patients. In all other patients, the appropriateness of biological therapy was uncertain, except for anti-TNF therapy in patients with a positive swab but without pneumonia in whom treatment was rated as appropriate. Tofacitinib was generally rated as inappropriate except in swab-negative patients in whom it was rated uncertain.

Finally, panellists were asked whether patients should be discharged with a period of ongoing prophylactic anticoagulation. This was deemed appropriate in patients who had a positive SARS-CoV-2 swab regardless of whether they had pneumonia but was rated uncertain in those who had negative swabs.

	1				
	Continuing medical therapy∞				
Negative COVID swab WITHOUT respiratory symptoms	Standard steroid taper	Accelerated steroid taper <4 weeks	°Thiopurine	°Ustekinumab	°Tofacitinib
	Accelerated steroid taper 4-6 weeks	◆Poorly bioavailable steroids	°Anti-TNF	°Vedolizumab	⊙Thromboprophylaxi
Positive COVID swab WITHOUT respiratory symptoms or signs of COVID pneumonia	Standard steroid taper	Accelerated steroid taper <4 weeks	°Thiopurine	°Ustekinumab	°Tofacitinib
	Accelerated steroid taper 4-6 weeks	◆Poorly bioavailable steroids	°Anti-TNF	°Vedolizumab	⊙Thromboprophylaxi
Positive COVID swab WITH symptoms or signs of COVID pneumonia	Standard steroid taper	Accelerated steroid taper <4 weeks	°Thiopurine	°Ustekinumab	°Tofacitinib
	Accelerated steroid taper 4-6 weeks	 Poorly bioavailable steroids 	°Anti-TNF	°Vedolizumab	⊙Thromboprophylaxi

Gut

Table 4. Appropriateness of treatment options in acute severe ulcerative colitis in the context of the COVID-19 pandemic: Continuing medical therapy. (Green is considered appropriate, yellow uncertain and red inappropriate). ∞Patient has responded to intravenous steroid therapy; •Switch from corticosteroids to budesonide MMX 9 mg daily/beclometasone 5 mg daily; °Steroid taper and start additional therapy at or soon after discharge; ⊙Continue for a period after discharge.

Discussion

General Considerations

The recent International Organisation For the Study of Inflammatory Bowel Disease (IOIBD) RAND appropriateness panel addressing the use of medications to treat IBD in the COVID-19 era did not specifically address the management of patients with ASUC.[17] To date, there has been no consensus on how to manage this condition during the COVID-19 pandemic; in the context of a limited, although rapidly evolving evidence base, this is perhaps unsurprising.[18] Thus, there is an urgent need for guidance on how best to manage ASUC in the current setting. Several areas need consideration in this regard including: the effect of SARS-CoV-2 on the activity and course of IBD; the effect of IBD and its activity on the risk of being infected with SARS-CoV-2 and the progression to COVID-19; the interaction of SARS-CoV-2/COVID-19 with the drugs used to treat IBD; and the possible effects of treatments for COVID-19 on IBD.

SARS-CoV-2 is found in the gut and RNA is measurable in the stool significantly longer than in serum or respiratory samples [19] although the significance of this is unclear. The effects of the virus on the intestinal mucosa remain undefined, as does its interaction with inflamed tissue.[20] Gastrointestinal symptoms including diarrhoea occur in around 30% of patients and have been associated with worse outcome [21,22] and a single report describes a possible case of COVID-19 colitis.[23]

Currently, it is not clear whether IBD-specific factors lead to worse outcomes in patients who develop COVID-19. In the Italian series of 79 patients with IBD and COVID-19, active disease was associated with the risk of COVID-19 pneumonia even after controlling for other risk factors.[12] Furthermore, active IBD was also significantly associated with increased hospitalisation, the need for respiratory support and death. In contrast, in Bergamo, Northern Italy, an observational study reported no cases of COVID-19 in 522 patients with IBD.[24] Whilst there are data that

Gut

suggest that active IBD increases the risk of some viral infections,[25] it is difficult to draw firm conclusions with regard to SARS-CoV-2 infection given the limited data available.

Of concern to most clinicians caring for patients with IBD is the possible risk of the drugs used to manage ASUC in the context of the COVID-19 pandemic. Intravenous corticosteroids remain the most widely used induction therapy in ASUC [26], but it is uncertain how they may influence outcome in patients with SARS-CoV-2 infection and COVID-19. Corticosteroids are known to increase the risk of sepsis and respiratory tract infections and may also increase viral replication and susceptibility to SARS-CoV-2.[27,28] There is also evidence that steroids may increase morbidity and/or mortality from some respiratory viruses such as influenza, Middle Eastern Respiratory Syndrome (MERS) and SARS-CoV, [27, 29–31] although steroids have an established role in the management of ARDS.[32] Beyond corticosteroids, immunomodulators such as thiopurines, biologics and tofacitinib are frequently used at various stages of the management of ASUC and there is also a lack of data regarding their safety in the context of the SARS-CoV-2 pandemic. Finally, it is important to consider the possible effects of drugs used to manage COVID-19 on IBD. For example, interleukin-6 inhibitors are being tested in patients with COVID-19 (ClinicalTrials.gov Identifier: NCT04315298) but have been associated with intestinal perforation in IBD.

We used an established methodology, a RAND appropriateness panel, to produce guidance in this challenging clinical area. Regarding initial management, there was agreement that all patients with ASUC should be managed as inpatients. Ambulatory care was considered inappropriate, since patients with ASUC need regular monitoring and involvement of a multi-disciplinary team, this type of complex care being difficult to deliver in the out-patient setting. Whilst there was some support for ambulatory management to avoid patients being admitted, thereby decreasing the risk of nosocomial acquisition of SARS-CoV-2, the risks of managing ASUC as an outpatient were considered to outweigh this possible benefit. Furthermore, in scenarios in which patients had confirmed SARS-CoV-2 infection, no such benefit existed. Nevertheless, in view of the acknowledged risk of contracting SARS-CoV-2 infection in hospital, it is perhaps unsurprising that the panel considered it appropriate to isolate patients with ASUC in a side room wherever possible.

The panel deemed it uncertain whether a CT chest should be performed in all patients on admission. While a CT chest is more sensitive than a chest x-ray (CXR) in detecting signs of early or limited infection, the COVID-19 specialists advised that a CXR would suffice in asymptomatic patients on admission. However, The Royal College of Radiologists has advised a low dose CT chest should be performed in patients who are having a CT abdomen as part of the investigation of an abdominal emergency.[33–35]

It was considered appropriate to involve a COVID-19 specialist in all scenarios in the presence of a positive SARS-CoV-2 swab, regardless of signs or symptoms of COVID-19 pneumonia. The panel was uncertain whether this was required in patients with a negative SARS-CoV-2 swab who required rescue therapy. During the meeting, concern was expressed by some panellists about the possible effects of corticosteroids and rescue therapies on SARS-CoV-2 infection and COVID-19 pneumonia driving the need to seek clarification from COVID experts and highlighting the need for further research.

First Line Therapy

It was considered appropriate to follow the BSG guidelines on the initial management of ASUC in patients without signs or symptoms of COVID-19, regardless of SARS-CoV-2 swab results. Only in patients with COVID-19 pneumonia was there uncertainty amongst the panel regarding the appropriateness of conventional therapy with intravenous corticosteroids, largely driven by concerns of possible harm. However, it should be noted that in this challenging condition in which there is scant experience and almost no published data in relation to COVID-19, of all suggested treatments, intravenous corticosteroids were given the highest median score by the panel. Regarding the ongoing uncertainty about the benefits or harms of corticosteroids in patients with COVID-19 pneumonia and the inconclusive data emerging from the current coronavirus pandemic, the results of the adaptive trial, RECOVERY, which

 Gut

includes a dexamethasone arm, are eagerly awaited.[1] Nevertheless, leaving ASUC untreated is associated with a high risk of death, mortality being at least 24% in the days before the use of corticosteroids.[26] The expert advisers supported the WHO position that steroid use should not be avoided because of theoretical risks in patients with COVID-19.[36]

The panel was uncertain whether infliximab, without concurrent corticosteroids, should be used as a first line therapy in patients who are SARS-CoV-2 positive, regardless of whether they had COVID-19. As with corticosteroids, the risk of anti-TNF in the context of the pandemic is unknown. In addition, there is no high-quality evidence for infliximab in ASUC other than as a rescue therapy following corticosteroid failure. Anti-TNF agents are known to increase the risk of respiratory tract and other opportunistic infections,[37] particularly when used in association with thiopurines and corticosteroids.[38] However, anti-TNF therapies are currently being evaluated in clinical trials [39] as a potential treatment for COVID-19-induced cytokine 'storm' [40,41]. In view of the uncertainty of the effects of corticosteroids and infliximab on SARS-CoV-2 infection, it was considered appropriate that all patients with a positive swab should be discussed with a COVID-19 specialist to guide decision making.

Rescue Therapy

Up to half of patients with ASUC fail first line medical therapy with corticosteroids.[6] In all scenarios, it was considered inappropriate to continue this treatment alone in the face of non-response at day 3, consistent with current BSG guidelines.[6] Similarly, in line with BSG guidance, it was considered appropriate to commence infliximab whilst continuing corticosteroids regardless of SARS-CoV-2 status. Discontinuation of corticosteroids at the point of commencing infliximab rescue therapy was considered of uncertain appropriateness across all scenarios, as it may result in worsening colitis, whilst acknowledging the potential risks of combining the two drugs. Ciclosporin rescue therapy was generally considered inappropriate, due in part to concerns about the risks of drug-induced nephrotoxicity given the frequency of acute kidney injury in SARS-CoV-2 infection.[42] In addition, the infusion regimen requires frequent healthcare worker-patient contact which could, in theory, increase the risk of transmission. The panel did not explore its use in settings in which infliximab may be relatively contraindicated, such as previous loss of response to infliximab, drug immunogenicity or when relevant co-morbidities exist, such as multiple sclerosis. Similarly, the panel did not specifically address the question of whether infliximab was used as a monotherapy or in combination with an immunomodulator.

There is little evidence regarding the risks of surgical management in patients with COVID-19. Preliminary data demonstrate a substantial increase in morbidity and mortality amongst SARS-CoV-2-infected patients undergoing surgery (*personal communication, submitted for publication*). In one report, 34 patients underwent elective surgery in Wuhan, China with all developing COVID-pneumonia, 7 of whom (20%) died.[9] Accordingly, the risks of surgery drove the rating of colectomy as first line therapy, or as an alternative to rescue therapy, as being inappropriate. However, in patients failing medical therapy, there was consensus that delaying surgery would be inappropriate.

Continuing Medical Therapy

The BSG IBD guidelines recommend corticosteroid tapering over 6-8 weeks which was considered appropriate by the panel, except in the context of COVID-19 pneumonia where an accelerated taper over 4-6 weeks was considered appropriate instead. A more accelerated taper, over fewer than 4 weeks, was generally deemed inappropriate due to the high risk of relapse in this cohort.[6] Regarding initiation of maintenance therapy either before or shortly after discharge from hospital, it was considered appropriate to start anti-TNF, vedolizumab or ustekinumab in patients with negative swabs. However, in scenarios in which patients had positive swabs, with or without evidence of COVID-19 pneumonia, there was uncertainty about the risk: benefit ratio of biologic therapy, driven by the lack of evidence. Thus, biologic use in this situation was deemed uncertain in nearly all scenarios.

Page 85 of 92

Gut

Thiopurines and tofacitinib were not considered appropriate at any stage during the scenarios. This is despite the BSG recommendation that thiopurines should be initiated at or soon after discharge following successful treatment of ASUC.[6] Azathioprine therapy was in part considered inappropriate due to possible side effects such as pancreatitis, which could result in readmission to hospital, and drug hypersensitivity, which can manifest as a flu-like syndrome which may potentially be confused with COVID-19.[43] Azathioprine can also induce significant lymphopaenia [43] which may mimic the lymphopaenia seen in SARS-CoV-2 infection. How this affects outcome of COVID-19 is unclear; some reports even suggest a theoretical benefit of thiopurines.[44,45] The additional monitoring required when azathioprine is initiated may also be a challenge with COVID-19-related service reconfiguration and antecedent risks of SARS-CoV-2 acquisition posed by the requirement for face-to-face contact from laboratory monitoring.

Tofacitinib is a non-selective Janus kinase (JAK) inhibitor which is associated with herpes zoster viral reactivation and, like COVID-19, is also associated with an increased risk of deep vein thrombosis.[46] There is also very limited evidence for its use in the setting of ASUC.[47] For these reasons, the panel considered its use inappropriate in nearly all settings although it was noted that its rapid offset of action could be of theoretical benefit.

Anticoagulation

Prophylactic anticoagulation was considered appropriate beyond discharge amongst patients with a positive SARS-CoV-2 swab, although this strategy was deemed uncertain in people with negative swabs. Like ASUC, COVID-19 is strongly linked to a hypercoagulable state with substantially increased risk of microthrombi and venous thromboembolism (VTE).[48] It is notable that the British Thoracic Society recommends doubling the dose of anticoagulation and/or prescribing VTE prophylaxis (low molecular weight heparin or direct oral anticoagulant) for up to 4 weeks following discharge in high risk patients with COVID-19.[49]

Page 86 of 92

Strengths & Limitations

The strengths of our study include the inclusion of a diverse group of IBD experts drawn from a wide range of UK centres as well as non-gastroenterology specialists with experience in managing patients with COVID-19. In addition, we used the RAND methodology which is a validated technique to guide decision making in the absence of a robust evidence base. It is not necessarily an attempt to reach consensus but rather to guide clinicians as to the appropriateness or inappropriateness of interventions, whilst accepting that uncertainty is also a valid outcome, which was highly appropriate in this setting. It was impossible for our scenarios to encompass fully all cases encountered in clinical practice. We, therefore, focussed on principles that may help to guide decision making in most cases of ASUC in the context of COVID-19. We appreciate that by doing so, this guidance may not be directly applicable to more nuanced cases where decision making may be influenced by a myriad of factors. Nor was every aspect of care considered; for example, the question of repeating testing for Clostridium difficile prior to colectomy in view of higher exposure to antibiotics in the COVID-19 era, was not addressed. The outcomes should, therefore, be considered an adjunct to multidisciplinary decision-making rather than a replacement. Finally, knowledge within the field remains fast moving such that it will be important to stay abreast of new developments as they arise.

Implications and concluding remarks

By combining clinical expertise from the BSG CRG and IBD Section Committee in conjunction with other medical and surgical IBD and <u>COVID-19</u> experts, we have provided guidance to clinicians regarding the appropriate management of ASUC during the COVID-19 pandemic, highlighting where current BSG guidance may need adaptation. Population-based studies are needed to clarify the risks and benefits of interventions used in the management of ASUC during the pandemic. Until then, we consider the results of the panel, which largely support following the well-established and evidence-based BSG guideline, will help guide clinicians in this challenging and evolving area.

Acknowledgments

The authors would like to acknowledge the input of Professor Jon Rhodes for his helpful comments and suggestions.

Funding The authors have declared no funding for this research

Competing interests Please see supplementary table 3

References

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;**395**:497–506. doi:10.1016/S0140-6736(20)30183-5
- Johns Hopkins University. Johns Hopkins Coronavirus Resource Center. 2020.https://coronavirus.jhu.edu/ (accessed 8 May 2020).
- The OpenSAFELY Collaborative, Williamson E, Walker AJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv Published Online First: 7 May 2020. doi:10.1101/2020.05.06.20092999
- Turner D, Walsh CM, Steinhart AH, et al. Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression. Clin Gastroenterol Hepatol 2007;5:103–10. doi:10.1016/j.cgh.2006.09.033
- Seah D, De Cruz P. Review article: the practical management of acute severe

> ulcerative colitis. *Aliment Pharmacol Ther* 2016;**43**:482–513. doi:10.1111/apt.13491

- 6 Lamb CA, Kennedy NA, Raine T, *et al.* British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;**68**:s1–106. doi:10.1136/gutjnl-2019-318484
- Rubin DT, Abreu MT, Rai V, *et al.* Management of Patients with Crohn's
 Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an
 International Meeting. *Gastroenterology* Published Online First: April 2020.
 doi:10.1053/j.gastro.2020.04.002
- Kirchgesner J, Lemaitre M, Carrat F, *et al.* Risk of Serious and Opportunistic
 Infections Associated With Treatment of Inflammatory Bowel Diseases.
 Gastroenterology 2018;155:337-346.e10. doi:10.1053/j.gastro.2018.04.012
- Lei S, Jiang F, Su W, *et al.* Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.
 Published Online First: 2020. doi:10.1016/j.eclinm.2020.100331
- 10 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955;**2**:1041–8.
- SECURE-IBD. SECURE-IBD Registry: Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion. 2020.https://covidibd.org/updatesand-data/
- Bezzio C, Saibeni S, Variola A, *et al.* Outcomes of COVID-19 in 79 patients with
 IBD in Italy: an IG-IBD study. *Gut* Published Online First: 30 April 2020.
 doi:10.1136/gutjnl-2020-321411
- 13 Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, et al. Characteristics and

Gut

	prognosis of patients with inflammatory bowel disease during the SARS-CoV-2
	pandemic in the Basque Country (Spain). <i>Gastroenterology</i> 2020; 0 .
	doi:10.1053/j.gastro.2020.04.043
14	Fitch K. Dernstein María SI. Aquilar D. et al. The DAND/UCLA Appropriatores
14	Fitch K, Bernstein María SJ, Aguilar D, <i>et al.</i> The RAND/UCLA Appropriateness
	Method User's Manual. 2001.
15	Coulter I, Elfenbaum P, Jain S, <i>et al.</i> SEaRCH [™] expert panel process:
	streamlining the link between evidence and practice. BMC Res Notes
	2016; 9 :16. doi:10.1186/s13104-015-1802-8
16	Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative
	colitis. <i>Gut</i> 1996; 38 :905–10. doi:10.1016/j.dld.2004.03.002
17	Rubin DT, Abreu MT, Rai V, <i>et al.</i> Management of Patients with Crohn's
	Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an
	International Meeting. Gastroenterology Published Online First: April 2020.
	doi:10.1053/j.gastro.2020.04.002
18	Al-Ani A, Prentice R, Rentsch C, et al. Review Article: Prevention, Diagnosis
	and Management of COVID-19 in the Inflammatory Bowel Disease Patient.
	Aliment Pharmacol Ther Published Online First: 29 April 2020.
	doi:10.1111/apt.15779
19	Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients
	infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020:
	retrospective cohort study. BMJ 2020;:m1443. doi:10.1136/bmj.m1443
20	
20	Ding S, Liang TJ. Journal Pre-proof Is SARS-CoV-2 Also an Enteric Pathogen
	with Potential Fecal-Oral Transmission: A COVID-19 Virological and Clinical
	Review. Gastroenterology Published Online First: 2020.
	doi:10.1053/j.gastro.2020.04.052

- Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020;115:766–73.
 doi:10.14309/ajg.0000000000000020
- 22 Mao R, Qiu Y, He J-S, *et al.* Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* Published Online First: May 2020. doi:10.1016/S2468-1253(20)30126-6
- Carvalho A, Alqusairi R, Adams A, et al. SARS-CoV-2 Gastrointestinal Infection
 Causing Hemorrhagic Colitis. Am J Gastroenterol 2020;:1.
 doi:10.14309/ajg.0000000000667
- 24 Norsa L, Indriolo A, Sansotta N, *et al.* Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. *Gastroenterology* Published Online First: April 2020. doi:10.1053/j.gastro.2020.03.062
- Wisniewski A, Kirchgesner J, Seksik P, *et al.* Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. *United Eur Gastroenterol J* Published Online First: 2019. doi:10.1177/2050640619889763
- Truelove SC, Witts LJ. Cortisone in Ulcerative Colitis. *BMJ* 1955;2:1041–8.doi:10.1136/bmj.2.4947.1041
- Van Kerkhove MD, Vandemaele KAH, Shinde V, et al. Risk Factors for Severe
 Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled
 Analysis. PLoS Med 2011;8:e1001053. doi:10.1371/journal.pmed.1001053
- 28 Lee N, Allen Chan KC, Hui DS, *et al.* Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J*

https://mc.manuscriptcentral.com/gut

Gut

<i>Clin Virol</i> 2004; 31 :304–9. doi:10.1016/j.jcv.2004.07.006
Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for
Critically III Patients with Middle East Respiratory Syndrome. Am J Respir Crit
Care Med 2018; 197 :757–67. doi:10.1164/rccm.201706-1172OC
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
corticosteroid treatment for 2019-nCoV lung injury. <i>Lancet</i> 2020; 395 :473–5.
doi:10.1016/S0140-6736(20)30317-2
Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as Adjunctive
Therapy in the Treatment of Influenza. <i>Crit Care Med</i> 2020; 48 :e98–106.
doi:10.1097/CCM.0000000000004093
Lewis SR, Pritchard MW, Thomas CM, et al. Pharmacological agents for adults
with acute respiratory distress syndrome. Cochrane Database Syst Rev
Published Online First: 23 July 2019. doi:10.1002/14651858.CD004477.pub3
The Royal College of Radiologists. Statement on use of CT chest to screen for
COVID-19 in pre-operative patients.
2020.https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-
doing/clinical-information/statement-use-ct-chest-screen-covid (accessed 8
May 2020).
Royal College of Surgeons. Updated Intercollegiate General Surgery Guidance
on COVID-19. 2020.https://www.rcseng.ac.uk/coronavirus/joint-guidance-for-
surgeons-v2/ (accessed 8 May 2020).
Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in
Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.
Radiology 2020;:200642. doi:10.1148/radiol.2020200642

- World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected.
 2020.https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus- (accessed 24 May 2020).
- Shah ED, Farida JP, Siegel CA, *et al.* Risk for Overall Infection with Anti-TNF and
 Anti-integrin Agents Used in IBD. *Inflamm Bowel Dis* 2017;23:570–7.
 doi:10.1097/MIB.00000000001049
- 38 Singh S, Facciorusso A, Dulai PS, *et al.* Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol* 2020;**18**:69-81.e3. doi:10.1016/j.cgh.2019.02.044
- Zhou L, Xu H. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). Chinese Clin. Trial Regist.
 2020.http://www.chictr.org.cn/showprojen.aspx?proj=49889 (accessed 13 May 2020).
- Feldmann M, Maini RN, Woody JN, *et al.* Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet* 2020;395:1407–9. doi:10.1016/S0140-6736(20)30858-8
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.
 doi:10.1016/S0140-6736(20)30628-0
- 42 Fanelli V, Fiorentino M, Cantaluppi V, *et al.* Acute kidney injury in SARS-CoV-2 infected patients. *Crit Care* 2020;**24**:155. doi:10.1186/s13054-020-02872-z
- 43 Chaparro M, Ordás I, Cabré E, et al. Safety of Thiopurine Therapy in

Gut

1 2		
3		Inflammatory Bowel Disease. Inflamm Bowel Dis 2013;19:1404–10.
4		
5 6		doi:10.1097/MIB.0b013e318281f28f
7		
8	44	Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory
9 10	44	
11		Distress Syndrome and Death in Patients With Coronavirus Disease 2019
12		Pneumonia in Wuhan, China. JAMA Intern Med Published Online First: 13
13 14		March 2020. doi:10.1001/jamainternmed.2020.0994
15		March 2020. doi.10.1001/juniamenined.2020.0354
16 17		
18	45	Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of
19		COVID-19: a descriptive and predictive study. Signal Transduct Target Ther
20 21		
22		2020; 5 :33. doi:10.1038/s41392-020-0148-4
23		
24 25	46	Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance
26		Therapy for Ulcerative Colitis. N Engl J Med 2017; 376 :1723–36.
27 28		
29		doi:10.1056/NEJMoa1606910
30		
31 32	47	Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe
33		
34 35		ulcerative colitis: a real-world experience. J Crohn's Colitis Published Online
36		First: 5 February 2020. doi:10.1093/ecco-jcc/jjaa018
37		
38 39	48	Middeldorp S, Coppens M, van Haaps TF, <i>et al.</i> Incidence of venous
40	40	
41 42		thromboembolism in hospitalized patients with COVID-19. Preprints.org
43		Published Online First: 2020. doi:10.20944/preprints202004.0345.v1
44		
45 46	40	Dritich Thomasia Conjety, DTC Cuidenes on Manaus Thrombourghalis Disease in
47	49	British Thoracic Society. BTS Guidance on Venous Thromboembolic Disease in
48 49		patients with COVID-19. Br. Thorac. Soc. 2020.https://www.brit-
50		thoracic.org.uk/document-library/quality-improvement/covid-19/bts-
51		guidance-on-venous-thromboembolic-disease-in-patients-with-covid-19/
52 53		
54		(accessed 8 May 2020).
55		
56 57		
58		
59 60		

Page 94 of 92

Gut

Confidential: For Review Only